: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Flying Publisher

The Angels Initiative

Stroke prevention

Chronic Heart Failure

Free Subscription

Articles published in Eur J Heart Fail
Retrieve available abstracts of 808 articles:
HTML format

Single Articles

March 2023

FUDIM M, Parikh K, Ganesh A, Molinger J, et al
Splanchnic Nerve Block with Botulinum Toxin for Therapy of Chronic Heart Failure - Mechanism of Action (SPONGE-HF).
Eur J Heart Fail. 2023 Mar 16. doi: 10.1002/ejhf.2829.
PubMed

ZANNAD F, Alikhaani J, Alikhaani S, Butler J, et al
PATIENT REPORTED OUTCOME MEASURES AND PATIENT ENGAGEMENT IN HEART FAILURE CLINICAL TRIALS: MULTI-STAKEHOLDER PERSPECTIVES.
Eur J Heart Fail. 2023 Mar 16. doi: 10.1002/ejhf.2828.
PubMed Abstract available

DOBBIN SJH, Shen L, Petrie MC, Packer M, et al
Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials.
Eur J Heart Fail. 2023 Mar 15. doi: 10.1002/ejhf.2818.
PubMed Abstract available

PANDEY AK, Dhingra NK, Pandey A, Puar P, et al
Efficacy of sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors for heart failure in black patients: a systematic review and meta-analysis of randomized controlled trials.
Eur J Heart Fail. 2023 Mar 15. doi: 10.1002/ejhf.2825.
PubMed

SAITO Y, Obokata M, Harada T, Kagami K, et al
Disproportionate exercise-induced pulmonary hypertension in relation to cardiac output in heart failure with preserved ejection fraction: a non-invasive echocardiographic study.
Eur J Heart Fail. 2023 Mar 13. doi: 10.1002/ejhf.2821.
PubMed Abstract available

PAGNESI M, Adamo M, Ter Maaten JM, Beldhuis IE, et al
Impact of mitral regurgitation in patients with acute heart failure: insights from the RELAX-AHF-2 trial.
Eur J Heart Fail. 2023 Mar 13. doi: 10.1002/ejhf.2820.
PubMed Abstract available

February 2023

BLUMER V, Truby LK, Zieroth S
Sex Differences in Heart Failure: The Evolving Use of Biomarkers.
Eur J Heart Fail. 2023 Feb 28. doi: 10.1002/ejhf.2817.
PubMed

PACKER M
Dosing of Iron Supplementation for Iron-Deficient Patients With Heart Failure: Should We Prefer More Intensive or Less Intensive Repletion Targets?
Eur J Heart Fail. 2023 Feb 28. doi: 10.1002/ejhf.2816.
PubMed

GUSTAFSSON F, Damman K, Nalbantgil S, Van Laake LW, et al
Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the ESC.
Eur J Heart Fail. 2023 Feb 27. doi: 10.1002/ejhf.2814.
PubMed Abstract available

GARD EK, Beale AL, Telles F, Silvestry FE, et al
Left atrial enlargement is associated with pulmonary vascular disease in heart failure with preserved ejection fraction.
Eur J Heart Fail. 2023 Feb 27. doi: 10.1002/ejhf.2805.
PubMed Abstract available

CHIONCEL O, Antohi L, Mebazaa A
Heart Failure and Non-cardiac Surgery: "A Call To Action" for Multidisciplinary Care Supporting Surgeons and Anesthesiologists.
Eur J Heart Fail. 2023 Feb 23. doi: 10.1002/ejhf.2813.
PubMed

FENG KY, Ambrosy AP, Zhou Z, Li D, et al
Association Between Serum Albumin and Outcomes in Heart Failure and Secondary Mitral Regurgitation: The COAPT Trial.
Eur J Heart Fail. 2023 Feb 23. doi: 10.1002/ejhf.2809.
PubMed Abstract available

GRAHAM FJ, Pellicori P, Kalra PR, Ford I, et al
Intravenous iron in patients with heart failure and iron deficiency: an updated meta-analysis.
Eur J Heart Fail. 2023 Feb 23. doi: 10.1002/ejhf.2810.
PubMed Abstract available

SANZ-RUIZ R, Perin EC, Fernandez-Aviles F
Cell Therapy for Heart Failure: Lessons Learned from SCIENCE.
Eur J Heart Fail. 2023 Feb 23. doi: 10.1002/ejhf.2807.
PubMed

MARCHANDOT B, Trimaille A, Morel O
Letter regarding the article "Acute heart failure after non-cardiac surgery: incidence, phenotypes, determinants and outcomes".
Eur J Heart Fail. 2023 Feb 23. doi: 10.1002/ejhf.2812.
PubMed

JANKOWSKA EA, Liu PP, Cowie MR, Groenhart M, et al
Personalised care of patients with heart failure - are we ready for a REWOLUTION? Insights from two international surveys on healthcare professionals' needs and patients' perceptions.
Eur J Heart Fail. 2023 Feb 23. doi: 10.1002/ejhf.2798.
PubMed Abstract available

Correction to: "A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry" and articles listed below.
Eur J Heart Fail. 2023 Feb 17. doi: 10.1002/ejhf.2789.
PubMed

MICHOU E, Wussler D, Mueller C
Reply to the Letter to the Editor regarding the article "Quantifying inflammation using Interleukin-6 for improved phenotyping and risk stratification in acute heart failure".
Eur J Heart Fail. 2023 Feb 15. doi: 10.1002/ejhf.2802.
PubMed

ABBASI MA, Borlaug BA
Pulmonary vascular disease in heart failure with preserved ejection fraction: the evidence grows.
Eur J Heart Fail. 2023 Feb 15. doi: 10.1002/ejhf.2800.
PubMed

LONCAR G, Garfias-Veitl T, Valentova M, Vatic M, et al
Bone status in men with heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure.
Eur J Heart Fail. 2023 Feb 13. doi: 10.1002/ejhf.2794.
PubMed Abstract available

CAPPELLETTO C, Stolfo D, Orsini N, Benson L, et al
Use of and Association between Heart Failure Pharmacological Treatments and Outcomes in Obese vs. non-Obese Patients with Heart Failure with Reduced Ejection Fraction: Data from the Swedish Heart Failure Registry.
Eur J Heart Fail. 2023 Feb 13. doi: 10.1002/ejhf.2795.
PubMed Abstract available

KALOGEROPOULOS AP, Lewis GD
Benefits of Intravenous Iron Supplementation in Patients with Heart Failure: Mounting Evidence and Open Questions.
Eur J Heart Fail. 2023 Feb 1. doi: 10.1002/ejhf.2787.
PubMed

PATEL L, Keshvani N, Pandey A
Are post-influenza vaccine reactions truly 'adverse'?
Eur J Heart Fail. 2023;25:311-312.
PubMed

DOMINGUEZ F, Cabrera E
Mavacamten in obstructive hypertrophic cardiomyopathy - Are beta-blockers blocking part of its shine?
Eur J Heart Fail. 2023;25:271-273.
PubMed

LIM HS, Yim IHW
De novo aortic regurgitation related to left ventricular assist device therapy: the difficult questions in need of new perspectives.
Eur J Heart Fail. 2023;25:295-298.
PubMed

OMOTE K, Verbrugge FH, Sorimachi H, Omar M, et al
Central haemodynamic abnormalities and outcome in patients with unexplained dyspnoea.
Eur J Heart Fail. 2023;25:185-196.
PubMed Abstract available

URIEL N, Milano C, Agarwal R, Lee S, et al
Incidence and clinical correlates of de-novo aortic regurgitation with a fully magnetically levitated left ventricular assist device: a MOMENTUM 3 trial portfolio analysis.
Eur J Heart Fail. 2023;25:286-294.
PubMed Abstract available

WHEELER MT, Jacoby D, Elliott PM, Saberi S, et al
Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
Eur J Heart Fail. 2023;25:260-270.
PubMed Abstract available

PEIKERT A, Claggett BL, Kim K, Udell JA, et al
Association of post-vaccination adverse reactions after influenza vaccine with mortality and cardiopulmonary outcomes in patients with high-risk cardiovascular disease: the INVESTED trial.
Eur J Heart Fail. 2023;25:299-310.
PubMed Abstract available

LEVI N, Moravsky G, Weitsman T, Amsalem I, et al
A prospective study on myocardial injury after BNT162b2 mRNA COVID-19 fourth dose vaccination in healthy persons.
Eur J Heart Fail. 2023;25:313-318.
PubMed Abstract available

January 2023

MCEWAN P, Harrison C, Binnie R, Lewis RD, et al
Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalisation: A European multinational economic evaluation.
Eur J Heart Fail. 2023 Jan 31. doi: 10.1002/ejhf.2788.
PubMed Abstract available

WANG S, Sun J, Wang L
Interleukin-6 in acute heart failure: it does work, but how much? Letter regarding the article 'Quantifying inflammation using Interleukin-6 for improved phenotyping and risk stratification in acute heart failure'.
Eur J Heart Fail. 2023 Jan 25. doi: 10.1002/ejhf.2785.
PubMed

FUCHS ANDERSEN C, Glenthoj A, Jensen J
Letter regarding the editorial "Little at a time: trying to understand the battery of benefits of SGLT2 inhibitors in heart failure".
Eur J Heart Fail. 2023 Jan 24. doi: 10.1002/ejhf.2782.
PubMed

WEENING EH, Al-Mubarak AA, Damman K, Voors AA, et al
Trace element equilibrium in acute heart failure and the effect of empagliflozin.
Eur J Heart Fail. 2023 Jan 24. doi: 10.1002/ejhf.2779.
PubMed

LECLERCQ C, Burri H
His bundle pacing for correcting atrioventricular dyssynchrony in heart failure: HYPE or HOPE?
Eur J Heart Fail. 2023 Jan 17. doi: 10.1002/ejhf.2775.
PubMed

GUALANDRO DM, Puelacher C, Chew MS, Andersson H, et al
Acute heart failure after non-cardiac surgery: incidence, phenotypes, determinants and outcomes.
Eur J Heart Fail. 2023 Jan 16. doi: 10.1002/ejhf.2773.
PubMed Abstract available

SAVARESE G, Lindenfeld J, Stolfo D, Adams K, et al
Use of Patient-Reported Outcomes in Heart Failure: From Clinical Trials to Routine Practice.
Eur J Heart Fail. 2023 Jan 16. doi: 10.1002/ejhf.2778.
PubMed Abstract available

MILLER RJ, Chew DS, Qin L, Fine NM, et al
Cost-effectiveness of immediate initiation of dapagliflozin in patients with a history of heart failure.
Eur J Heart Fail. 2023 Jan 16. doi: 10.1002/ejhf.2777.
PubMed Abstract available

MASTORIS I, Campain J, Lewis GD
Invasive Exercise Hemodynamics: An Oracle in Heart Failure with Preserved Ejection Fraction Diagnosis and Prognostication.
Eur J Heart Fail. 2023 Jan 16. doi: 10.1002/ejhf.2774.
PubMed

QAYYUM AA, van Klarenbosch B, Frljak S, Cerar A, et al
Effect of allogeneic adipose tissue derived mesenchymal stromal cell treatment in chronic ischemic heart failure with reduced ejection fraction - The SCIENCE Trial.
Eur J Heart Fail. 2023 Jan 16. doi: 10.1002/ejhf.2772.
PubMed Abstract available

ORBAN M, Rottbauer W, Williams M, Mahoney P, et al
Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation with 3(rd) Generation Devices in Heart Failure Patients-Results from the Global EXPAND Post-Market Study.
Eur J Heart Fail. 2023 Jan 4. doi: 10.1002/ejhf.2770.
PubMed Abstract available

AIMO A, Bayes-Genis A
Biomarkers of inflammation in heart failure: from risk prediction to possible treatment targets.
Eur J Heart Fail. 2023 Jan 4. doi: 10.1002/ejhf.2771.
PubMed

GRASSI G
HEART FAILURE RELATED CENTRAL SYMPATHETIC ACTIVATION: DEBUNKING THE "HOLY GRAIL" ?
Eur J Heart Fail. 2023 Jan 4. doi: 10.1002/ejhf.2764.
PubMed

MICHOU E, Wussler D, Belkin M, Simmen C, et al
Quantifying inflammation using Interleukin-6 for improved phenotyping and risk stratification in acute heart failure.
Eur J Heart Fail. 2023 Jan 4. doi: 10.1002/ejhf.2767.
PubMed Abstract available

VON HAEHLING S, Sato R, Butler J, Anker SD, et al
Little at a time: trying to understand the battery of benefits of SGLT2 inhibitors in heart failure.
Eur J Heart Fail. 2023 Jan 4. doi: 10.1002/ejhf.2766.
PubMed

VARSHNEY AS, Berg DD, Zhou G, Sinnenberg L, et al
Bridging Strategies and Cardiac Replacement Outcomes in Patients with Acute Decompensated Heart Failure-Related Cardiogenic Shock.
Eur J Heart Fail. 2023 Jan 4. doi: 10.1002/ejhf.2762.
PubMed Abstract available

DOCHERTY KF, McMurray JJV, Claggett BL, Miao ZM, et al
Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: Insights from the GALACTIC-HF trial.
Eur J Heart Fail. 2023 Jan 4. doi: 10.1002/ejhf.2763.
PubMed Abstract available

VAN DER HOEF CCS, Boorsma EM, Emmens JE, van Essen BJ, et al
Biomarker signature and pathophysiological pathways in chronic heart failure patients with metabolic syndrome.
Eur J Heart Fail. 2023 Jan 4. doi: 10.1002/ejhf.2760.
PubMed Abstract available

TOMASONI D, Adamo M, Metra M
January 2023 at a glance: focus on acute heart failure and medical therapy.
Eur J Heart Fail. 2023;25:1-3.
PubMed

CARAVITA S, Baratto C
Understanding mechanisms of Fontan failure: exercise haemodynamics to unmask diastolic dysfunction, again!
Eur J Heart Fail. 2023;25:26-29.
PubMed

CODINA P, Lupon J, Subirana I, Zamora E, et al
Barcelona Bio-HF calculator version 3.0: recalibration and incorporation of sodium-glucose cotransporter 2 inhibitor treatment.
Eur J Heart Fail. 2023;25:131-132.
PubMed

BERTERO E, Maack C
The attack of the clones to the cardiovascular system.
Eur J Heart Fail. 2023;25:14-16.
PubMed

YU Y, Niu H, Hua W
Letter regarding the article 'Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure'.
Eur J Heart Fail. 2023;25:133.
PubMed

December 2022

BORIANI G, Imberti JF, Vitolo M
The burden of atrial fibrillation in patients with preserved or mildly reduced heart failure: a call to action for detecting atrial fibrillation and improving outcome.
Eur J Heart Fail. 2022 Dec 15. doi: 10.1002/ejhf.2755.
PubMed

KALOGEROPOULOS AP, Jacobs M
Improve Heart Function to Improve Heart Failure Outcomes: The Disease-Modifying Effects of Spironolactone.
Eur J Heart Fail. 2022 Dec 15. doi: 10.1002/ejhf.2757.
PubMed

CARBONE S, daSilva-deAbreu A, Lavie CJ
Weighing in on Weight Loss in Heart Failure with Reduced Ejection Fraction.
Eur J Heart Fail. 2022 Dec 15. doi: 10.1002/ejhf.2753.
PubMed

COTTER G, Davison B, Cohen-Solal A, Freund Y, et al
Targeting the "vulnerable" period - first 3 - 6 months after an acute heart failure admission - the light gets brighter.
Eur J Heart Fail. 2022 Dec 15. doi: 10.1002/ejhf.2754.
PubMed

HUNGERFORD SL, Dahle G, Duncan A, Hayward CS, et al
Peri-procedural management of transcatheter mitral valve replacement in patients with heart failure.
Eur J Heart Fail. 2022 Dec 15. doi: 10.1002/ejhf.2758.
PubMed Abstract available

INCIARDI R, Pellicori P, Chandra A
Identification and Quantification of Congestion in Heart Failure: a Work in Progress.
Eur J Heart Fail. 2022 Dec 4. doi: 10.1002/ejhf.2751.
PubMed

BADROV MB, Keir DA, Tomlinson G, Notarius CF, et al
Normal and excessive muscle sympathetic nerve activity in heart failure: implications for future trials of therapeutic autonomic modulation.
Eur J Heart Fail. 2022 Dec 2. doi: 10.1002/ejhf.2749.
PubMed Abstract available

TOMASONI D, Adamo M, Metra M
December 2022 at a glance: heart failure with preserved ejection fraction, sodium-glucose cotransporter 2 inhibitors and cardiac amyloidosis.
Eur J Heart Fail. 2022;24:2209-2211.
PubMed

PATEL RK, Ioannou A, Razvi Y, Chacko L, et al
Sex differences among patients with transthyretin amyloid cardiomyopathy - from diagnosis to prognosis.
Eur J Heart Fail. 2022;24:2355-2363.
PubMed Abstract available

CERLINSKAITE-BAJORE K, Mebazaa A, Celutkiene J
Guideline-directed medical therapy improves not only left but also right heart function.
Eur J Heart Fail. 2022;24:2235-2237.
PubMed

CHANDRA A, Polanczyk CA, Claggett BL, Vaduganathan M, et al
Health-related quality of life outcomes in PARAGON-HF.
Eur J Heart Fail. 2022;24:2264-2274.
PubMed Abstract available

DOMINGUEZ-RODRIGUEZ A, Hernandez-Vaquero D, Miro O
Reply to 'Morphine use in acute cardiogenic pulmonary oedema: is MIMO trial enough to change practice?'.
Eur J Heart Fail. 2022;24:2393-2394.
PubMed

NETO GONCALVES T, Margarida Andrade M
Morphine use in acute cardiogenic pulmonary oedema: is MIMO trial enough to change practice? Letter regarding the article 'Midazolam versus morphine in acute cardiogenic pulmonary oedema: results of a multicentre, open-label, randomized controlled tri
Eur J Heart Fail. 2022;24:2392-2393.
PubMed

NICKLAS JM, Perry D
Non-intuitive findings from the MEMS-HF haemodynamic substudy.
Eur J Heart Fail. 2022;24:2331-2332.
PubMed

NITSCHE C
How prevalent is cardiac amyloidosis and which patients should be screened?
Eur J Heart Fail. 2022;24:2352-2354.
PubMed

RAPEZZI C, Emdin M, Aimo A
Unravelling the role of sex in the pathophysiology, phenotypic expression and diagnosis of cardiac amyloidosis.
Eur J Heart Fail. 2022;24:2364-2366.
PubMed Abstract available

MAESTRO-BENEDICTO A, Vela P, de Frutos F, Mora N, et al
Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
Eur J Heart Fail. 2022;24:2367-2373.
PubMed Abstract available

AIMO A, Merlo M, Porcari A, Georgiopoulos G, et al
Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies.
Eur J Heart Fail. 2022;24:2342-2351.
PubMed Abstract available

November 2022

SINHA A, Patel RB
Loop diuretic management after sacubitril/valsartan initiation in heart failure with preserved ejection fraction: deceptively simple or more than meets the eye?
Eur J Heart Fail. 2022 Nov 29. doi: 10.1002/ejhf.2750.
PubMed

LIN DS, Lin FI, Lin YS, Lee JK, et al
The Effects of Mineralocorticoid Receptor Antagonists on Cardiovascular Outcomes in Patients With End-Stage Renal Disease and Heart Failure.
Eur J Heart Fail. 2022 Nov 20. doi: 10.1002/ejhf.2740.
PubMed Abstract available

GARCIA-ALVAREZ A, Blanco I, Garcia-Lunar I, Jorda P, et al
beta3-adrenergic agonist treatment in chronic pulmonary hypertension associated with heart failure (SPHERE-HF): a double blind, placebo-controlled, randomized clinical trial.
Eur J Heart Fail. 2022 Nov 20. doi: 10.1002/ejhf.2745.
PubMed Abstract available

FAUVEL C, Bonnet G, Mullens W, Giraldo CIS, et al
Sequencing and titrating approach of therapy in heart failure with reduced ejection fraction following the 2021 European Society of Cardiology guidelines: an international cardiology survey.
Eur J Heart Fail. 2022 Nov 20. doi: 10.1002/ejhf.2743.
PubMed Abstract available

WHINNETT ZI, Shun-Shin MJ, Tanner M, Foley P, et al
Effects of haemodynamically atrio-ventricular optimized His-pacing on heart failure symptoms and exercise capacity: The His Optimized Pacing Evaluated for Heart Failure (HOPE-HF) randomised, double-blind, cross-over trial.
Eur J Heart Fail. 2022 Nov 20. doi: 10.1002/ejhf.2736.
PubMed Abstract available

MOHEBI R, Liu Y, van Kimmenade R, Gaggin HK, et al
Inflammation across Universal Definition of Heart Failure Stages: The CASABLANCA Study.
Eur J Heart Fail. 2022 Nov 17. doi: 10.1002/ejhf.2742.
PubMed Abstract available

PATEL HC, Kaye DM
SGLT2i: Efficacious and Safe in Elderly Patients with Heart Failure.
Eur J Heart Fail. 2022 Nov 17. doi: 10.1002/ejhf.2744.
PubMed

VAN WOERDEN G, van Veldhuisen DJ, Westenbrink BD, de Boer RA, et al
Connecting Epicardial Adipose Tissue and Heart Failure with Preserved Ejection Fraction: Mechanisms, Management and Modern Perspectives.
Eur J Heart Fail. 2022 Nov 17. doi: 10.1002/ejhf.2741.
PubMed Abstract available

PACKER M
How Can SGLT2 Inhibitors Stimulate Erythrocytosis in Patients Who Are Iron Deficient? Implications for Understanding Iron Hemostasis in Heart Failure.
Eur J Heart Fail. 2022 Nov 14. doi: 10.1002/ejhf.2731.
PubMed Abstract available

DE BIASE N, Del Punta L, Pugliese NR
The dangerous liaison between epicardial adipose tissue and heart failure with preserved ejection fraction.
Eur J Heart Fail. 2022 Nov 14. doi: 10.1002/ejhf.2733.
PubMed

FUCHS ANDERSEN C, Omar M, Glenthoj A, El Fassi D, et al
Effects of Empagliflozin on Erythropoiesis in Heart Failure: Data from the Empire HF Trial.
Eur J Heart Fail. 2022 Nov 14. doi: 10.1002/ejhf.2735.
PubMed Abstract available

LERMAN JB, Felker GM
Time to Diuretics in Acute Heart Failure: the tortoise or the hare?
Eur J Heart Fail. 2022 Nov 9. doi: 10.1002/ejhf.2732.
PubMed

PATEL RB, Greene SJ, Xu H, Alhanti B, et al
Intersection of Atrial Fibrillation and Heart Failure with Mildly Reduced and Preserved Ejection Fraction in >400,000 Participants in the Get With The Guidelines Heart Failure Registry.
Eur J Heart Fail. 2022 Nov 7. doi: 10.1002/ejhf.2729.
PubMed Abstract available

YANG M, Butt JH, Kondo T, Jering KS, et al
Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan.
Eur J Heart Fail. 2022 Nov 7. doi: 10.1002/ejhf.2722.
PubMed Abstract available

GREENE SJ, Goto D, Wang D, Hilkert R, et al
Outpatient versus Inpatient Intravenous Diuretic Therapy for Heart Failure in the United States.
Eur J Heart Fail. 2022 Nov 5. doi: 10.1002/ejhf.2727.
PubMed

ANKER SD, Khan MS, Butler J, Ofstad AP, et al
Weight Change and Clinical Outcomes in Heart Failure with Reduced Ejection Fraction: Insights from EMPEROR-Reduced.
Eur J Heart Fail. 2022 Nov 2. doi: 10.1002/ejhf.2728.
PubMed Abstract available

ADAMO M, Pagnesi M, Ghizzoni G, Estevez-Loureiro R, et al
Evolution of tricuspid regurgitation after transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation and its impact on mortality.
Eur J Heart Fail. 2022;24:2175-2184.
PubMed Abstract available

TOMASONI D, Adamo M, Metra M
November 2022 at a glance: focus on epidemiology, prognosis and comorbidities.
Eur J Heart Fail. 2022;24:1997-1999.
PubMed

MARTINO M, Sannino A
From forgotten to rediscovered: shifting focus to the right ventricle in primary mitral regurgitation.
Eur J Heart Fail. 2022;24:2172-2174.
PubMed

JHUND PS
Implementing the evidence - the true summit of evidence-based care and the false peak of guidelines.
Eur J Heart Fail. 2022;24:2090-2092.
PubMed

CEDARS A, Joseph S
Don't tell your patients where they are, let them tell you.
Eur J Heart Fail. 2022;24:2105-2107.
PubMed

HEIDECKER B, Dagan N, Balicer R, Eriksson U, et al
Myocarditis following COVID-19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ES
Eur J Heart Fail. 2022;24:2000-2018.
PubMed Abstract available

DOLDI PM, Stolz L, Kalbacher D, Koll B, et al
Right ventricular dysfunction predicts outcome after transcatheter mitral valve repair for primary mitral valve regurgitation.
Eur J Heart Fail. 2022;24:2162-2171.
PubMed Abstract available

VERGARO G, Aimo A, Rapezzi C, Castiglione V, et al
Atrial amyloidosis: mechanisms and clinical manifestations.
Eur J Heart Fail. 2022;24:2019-2028.
PubMed Abstract available

STANTON LJ, Dershowitz LB, Lang KJ, Brandwein R, et al
Insights from a clinical heart valve centre: characteristics and management of functional mitral regurgitation.
Eur J Heart Fail. 2022;24:2202-2205.
PubMed

HIGUCHI S, Orban M, Adamo M, Giannini C, et al
Guideline-directed medical therapy in patients undergoing transcatheter edge-to-edge repair for secondary mitral regurgitation.
Eur J Heart Fail. 2022;24:2152-2161.
PubMed Abstract available

October 2022

FERREIRA JP, Cleland JG, Girerd N, Bozec E, et al
Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials.
Eur J Heart Fail. 2022 Oct 27. doi: 10.1002/ejhf.2726.
PubMed Abstract available

BATRA G, Aktaa S, Benson L, Dahlstrom U, et al
Association between heart failure quality of care and mortality: population-based cohort study using nationwide registries.
Eur J Heart Fail. 2022 Oct 27. doi: 10.1002/ejhf.2725.
PubMed Abstract available

PATEL KV, Khan MS, Segar MW, Bahnson JL, et al
Optimal Cardiometabolic Health and Risk of Heart Failure in Type 2 Diabetes: An Analysis from the Look AHEAD Trial.
Eur J Heart Fail. 2022 Oct 24. doi: 10.1002/ejhf.2723.
PubMed Abstract available

ANSARI RAMANDI MM, van Melle JP, Gorter TM, Hoendermis ES, et al
Right ventricular dysfunction in patients with new-onset heart failure: Longitudinal follow-up during guideline-directed medical therapy.
Eur J Heart Fail. 2022 Oct 17. doi: 10.1002/ejhf.2721.
PubMed Abstract available

BUTLER J, Usman MS, Anstrom KJ, Blaustein RO, et al
Soluble Guanylate Cyclase Stimulators in Patients with Heart Failure with Reduced Ejection Fraction Across the Risk Spectrum.
Eur J Heart Fail. 2022 Oct 17. doi: 10.1002/ejhf.2720.
PubMed Abstract available

DE LA ESPRIELLA R, Bayes-Genis A, Nunez J
Bending Oxygen Saturation index (BOSI) and Risk of Worsening Heart Failure Events in Chronic Heart Failure.
Eur J Heart Fail. 2022 Oct 12. doi: 10.1002/ejhf.2717.
PubMed

BRANCH KRH, Gerstein HC, Probstfield JL
Letter regarding the article Dulaglutide and Cardiovascular and Heart Failure Outcomes in Patients With and Without Heart Failure: A Post-Hoc Analysis from the REWIND Randomized Trial: Reply.
Eur J Heart Fail. 2022 Oct 12. doi: 10.1002/ejhf.2719.
PubMed

ZHANG Y, Feng J, Zhang J
Heart failure with preserved ejection fraction in China: An urgent need for improving the management.
Eur J Heart Fail. 2022 Oct 11. doi: 10.1002/ejhf.2718.
PubMed

SHI C, Aboumsallem JP, Suthahar N, de Graaf AO, et al
Clonal hematopoiesis of indeterminate potential: associations with heart failure incidence, clinical parameters and biomarkers.
Eur J Heart Fail. 2022 Oct 11. doi: 10.1002/ejhf.2715.
PubMed Abstract available

ZAKERI R, Ahluwalia N, Tindale A, Omar F, et al
Long-term outcomes following catheter ablation versus medical therapy in patients with persistent atrial fibrillation and heart failure with reduced ejection fraction.
Eur J Heart Fail. 2022 Oct 11. doi: 10.1002/ejhf.2714.
PubMed Abstract available

INCIARDI RM, Pagnesi M, Lombardi CM, Solomon SD, et al
Reply to "Clinical implications of left atrial changes after optimization of medical therapy in heart failure patients".
Eur J Heart Fail. 2022 Oct 11. doi: 10.1002/ejhf.2713.
PubMed

VENKATESHVARAN A, Faxen UL, Hage C, Michaelsson E, et al
Association of Epicardial Adipose Tissue with Proteomics, Coronary Flow Reserve, Cardiac Structure and Function, and Quality of Life in Heart Failure with Preserved Ejection Fraction: Insights from the PROMIS-HFpEF study.
Eur J Heart Fail. 2022 Oct 4. doi: 10.1002/ejhf.2709.
PubMed Abstract available

OUWERKERK W, Tromp J, Cleland JGF, Angermann CE, et al
Association of time-to-IV-furosemide with mortality in acute heart failure: data from REPORT-HF.
Eur J Heart Fail. 2022 Oct 4. doi: 10.1002/ejhf.2708.
PubMed Abstract available

FILIPPATOS G, Anker SD, Butler J, Farmakis D, et al
Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: A secondary analysis of EMPEROR-Reduced.
Eur J Heart Fail. 2022 Oct 4. doi: 10.1002/ejhf.2707.
PubMed Abstract available

MIRANDA WR, Borlaug BA, Jain CC, Anderson JH, et al
Exercise-induced changes in pulmonary artery wedge pressure in adults post-Fontan versus heart failure with preserved ejection fraction and noncardiac dyspnea.
Eur J Heart Fail. 2022 Oct 4. doi: 10.1002/ejhf.2706.
PubMed Abstract available

MARTENS P
Inhibiting the proximal nephron in acute heart failure - emerging data on kidney safety and efficacy.
Eur J Heart Fail. 2022 Oct 4. doi: 10.1002/ejhf.2711.
PubMed

CHATUR S, Claggett BL, Vardeny O, Jering K, et al
Sacubitril/Valsartan and Loop Diuretic Requirement in Heart Failure with Preserved Ejection Fraction in the PARAGON-HF Trial.
Eur J Heart Fail. 2022 Oct 1. doi: 10.1002/ejhf.2703.
PubMed Abstract available

ARONSON D
Can subgroup analyses in randomized trials guide individualized patient care?
Eur J Heart Fail. 2022;24:1802-1804.
PubMed

CHATUR S, Lakdawala NK, Cunningham JW
Random admission urinary sodium for diuretic response: promise in pragmatism?
Eur J Heart Fail. 2022;24:1988-1989.
PubMed

CHIONCEL O, Metra M
Morphine in acute pulmonary oedema: a signal of harm but more questions than answers.
Eur J Heart Fail. 2022;24:1963-1966.
PubMed

BERWANGER O, Pfeffer M, Claggett B, Jering KS, et al
Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial.
Eur J Heart Fail. 2022;24:1918-1927.
PubMed Abstract available

BELDHUIS IE, Martens P, Ter Maaten JM
Early changes in renal function after sodium-glucose cotransporter 2 inhibitor initiation in EMPEROR-Reduced: the end of the dilemma?
Eur J Heart Fail. 2022;24:1840-1843.
PubMed

PAPPALARDO F, Tavazzi G, Savonitto S, Morici N, et al
Enrolling patients in cardiogenic shock trials: are we missing someone? Insights from the Italian AltShock-2 registry.
Eur J Heart Fail. 2022;24:1748-1750.
PubMed

MOHR E, Thum T, Bar C
Accelerating cardiovascular research: recent advances in translational 2D and 3D heart models.
Eur J Heart Fail. 2022;24:1778-1791.
PubMed Abstract available

DOMINGUEZ-RODRIGUEZ A, Suero-Mendez C, Burillo-Putze G, Gil V, et al
Midazolam versus morphine in acute cardiogenic pulmonary oedema: results of a multicentre, open-label, randomized controlled trial.
Eur J Heart Fail. 2022;24:1953-1962.
PubMed Abstract available

ZANNAD F, Ferreira JP, Gregson J, Kraus BJ, et al
Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Reduced.
Eur J Heart Fail. 2022;24:1829-1839.
PubMed Abstract available

September 2022

KEIR DA, Floras JS
Iron repletion in heart failure: a central chemoreceptor reflex tonic?
Eur J Heart Fail. 2022 Sep 25. doi: 10.1002/ejhf.2697.
PubMed

BAEZA-TRINIDAD R, Mosquera-Lozano JD
"Bending Oxygen Saturation Index (BOSI) and Risk of Worsening Heart Failure Events in Chronic Heart Failure": A letter to the editor.
Eur J Heart Fail. 2022 Sep 25. doi: 10.1002/ejhf.2701.
PubMed

PARVAN R, Hosseinpour M, Moradi Y, Devaux Y, et al
Diagnostic Performance of MicroRNAs in the Detection of Heart Failure with Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
Eur J Heart Fail. 2022 Sep 25. doi: 10.1002/ejhf.2700.
PubMed Abstract available

LEE MMY, Campbell RT, Claggett BL, Lewis EF, et al
Health-related quality of life in acute heart failure: Association between patient-reported symptoms and markers of congestion.
Eur J Heart Fail. 2022 Sep 25. doi: 10.1002/ejhf.2699.
PubMed Abstract available

PELLICORI P, Kalra PR, Clark AL, Friday JM, et al
CKD and CKD-ism in heart failure - what a mess!
Eur J Heart Fail. 2022 Sep 21. doi: 10.1002/ejhf.2696.
PubMed

Corrigendum to 'Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata' [Eur J Heart Fail 2022;24:1047-1062].
Eur J Heart Fail. 2022 Sep 20. doi: 10.1002/ejhf.2691.
PubMed

FERREIRA JP, Neves JS
Letter regarding the article 'Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial.
Eur J Heart Fail. 2022 Sep 17. doi: 10.1002/ejhf.2694.
PubMed

COOPER TJ, Pellicori P, Ushakova A, Dickstein K, et al
Reply to the letter "Particular Challenges in the Use of Pulmonary Vasodilating Therapy for Patients with Pulmonary Hypertension Secondary to Left Heart Diseases".
Eur J Heart Fail. 2022 Sep 17. doi: 10.1002/ejhf.2690.
PubMed

VAN ESSEN BJ, Tromp J, Ter Maaten JM, Greenberg BH, et al
Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction.
Eur J Heart Fail. 2022 Sep 16. doi: 10.1002/ejhf.2695.
PubMed Abstract available

DE LA ESPRIELLA R, Bayes-Genis A, Nunez J
Bending Oxygen Saturation index (BOSI) and Risk of Worsening Heart Failure Events in Chronic Heart Failure.
Eur J Heart Fail. 2022 Sep 14. doi: 10.1002/ejhf.2692.
PubMed

FERREIRA JP, Neves JS
Glucagon-Like Peptide 1 Receptor Agonists in Heart Failure: the need for a rewind.
Eur J Heart Fail. 2022 Sep 14. doi: 10.1002/ejhf.2693.
PubMed

JOURY A, Razaghizad A, Sharma A
Multi-Biomarkers Approach to Predict Survival and Adverse Cardiovascular Events Among Patients with Heart Failure with Preserved Ejection Fraction.
Eur J Heart Fail. 2022 Sep 13. doi: 10.1002/ejhf.2689.
PubMed

Corrigendum to 'Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction' [Eur J Heart Fail 2022;24:782-790].
Eur J Heart Fail. 2022 Sep 13. doi: 10.1002/ejhf.2676.
PubMed

GREENE SJ, Fonarow GC, Butler J
SGLT2 Inhibitors for Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Time to Deliver Implementation.
Eur J Heart Fail. 2022 Sep 13. doi: 10.1002/ejhf.2688.
PubMed

ADAMSON C, Jhund PS, McMurray JJ
Reply: Liver function tests and outcomes in heart failure with reduced ejection fraction: Findings from DAPA-HF.
Eur J Heart Fail. 2022 Sep 12. doi: 10.1002/ejhf.2683.
PubMed

MCDOWELL K, Jhund PS, McMurray JJ
Reply to 'Sodium-glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction - lessons from clinical trials'. Letter regarding the article 'Dapagliflozin reduces uric acid concentrat
Eur J Heart Fail. 2022 Sep 12. doi: 10.1002/ejhf.2686.
PubMed

GIRERD N
Worsening renal function precedes and follows worsening heart failure.
Eur J Heart Fail. 2022 Sep 11. doi: 10.1002/ejhf.2673.
PubMed

BUTLER J, Siddiqi TJ, Anker SD
Patiromer Use in Patients with Heart Failure Lessons and Clinical Considerations from the DIAMOND Trial.
Eur J Heart Fail. 2022 Sep 11. doi: 10.1002/ejhf.2684.
PubMed

BOHM M, Butler J, Mahfoud F, Filippatos G, et al
Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved Trial.
Eur J Heart Fail. 2022 Sep 10. doi: 10.1002/ejhf.2677.
PubMed Abstract available

BRANCH KRH, Dagenais GR, Avezum A, Basile J, et al
Dulaglutide and Cardiovascular and Heart Failure Outcomes in Patients With and Without Heart Failure: A Post-hoc Analysis from the REWIND Randomized Trial.
Eur J Heart Fail. 2022 Sep 8. doi: 10.1002/ejhf.2670.
PubMed Abstract available

BAYES-GENIS A, Aimo A, Jhund P, Richards AM, et al
A review from the Biomarkers Working Group of the Heart Failure Association of the ESC: A review from the Biomarkers Working Group of the Heart Failure Association of the ESC.
Eur J Heart Fail. 2022 Sep 8. doi: 10.1002/ejhf.2675.
PubMed Abstract available

VOORS AA, Damman K, Teerlink JR, Angermann CE, et al
Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial.
Eur J Heart Fail. 2022 Sep 6. doi: 10.1002/ejhf.2681.
PubMed Abstract available

NAHAR TAK, Shah A, Ahmad M
"Bending Oxygen Saturation Index (BOSI) and Risk of Worsening Heart Failure Events in Chronic Heart Failure": A letter to the editor.
Eur J Heart Fail. 2022 Sep 6. doi: 10.1002/ejhf.2679.
PubMed

KRAWCZYK M, Bohm M
The 50 shades of bilirubin.
Eur J Heart Fail. 2022 Sep 6. doi: 10.1002/ejhf.2671.
PubMed

LUND LH, Eldhagen P
Diagnosing heart failure with preserved ejection fraction in cardiac amyloidosis or diagnosing cardiac amyloidosis in heart failure with preserved ejection fraction?
Eur J Heart Fail. 2022 Sep 6. doi: 10.1002/ejhf.2678.
PubMed

XIE C, Zhang Y, Lin J
What is the optimal dose of neurohormonal modulators in patients with heart failure? The higher the better?
Eur J Heart Fail. 2022 Sep 4. doi: 10.1002/ejhf.2668.
PubMed

JHUND PS
Cardiopulmonary functional capacity: Another piece of the puzzle of SGLT2 inhibition in heart failure?
Eur J Heart Fail. 2022 Sep 2. doi: 10.1002/ejhf.2672.
PubMed

TOMASONI D, Adamo M, Metra M
September 2022 at a glance.
Eur J Heart Fail. 2022;24:1455-1457.
PubMed

ROSANO GMC, Metra M, Volterrani M
The strategic vision of the 2022-2024 mandate - greater involvement of members, young specialists for an HFA community without borders.
Eur J Heart Fail. 2022;24:1458-1459.
PubMed

MEEKERS E, Mullens W
When is the time right? Dancing on the tightrope: referral for upgrade to cardiac resynchronization therapy.
Eur J Heart Fail. 2022;24:1662-1664.
PubMed

BUTT JH, McMurray JJV
Vericiguat, sacubitril/valsartan and more evidence that we are failing our patients.
Eur J Heart Fail. 2022;24:1623-1624.
PubMed

PORCARI A, Merlo M, Sinagra G
Time to reconsider thromboembolic risk and anticoagulation in transthyretin cardiac amyloidosis?
Eur J Heart Fail. 2022;24:1716-1718.
PubMed

MUSIGK N, Heidecker B
Transthyretin amyloidosis: the picture is getting clearer.
Eur J Heart Fail. 2022;24:1697-1699.
PubMed

NITSCHE C
Echocardiographic tracking of transthyretin cardiomyopathy: which parameters matter the most?
Eur J Heart Fail. 2022;24:1713-1715.
PubMed

BAUERSACHS J, Koenig T
Peripartum cardiomyopathy - a global challenge.
Eur J Heart Fail. 2022;24:1737-1738.
PubMed

ALVAREZ-GARCIA J
Sacubitril/valsartan adherence... because the best is sometimes difficult to replace the good.
Eur J Heart Fail. 2022;24:1516-1518.
PubMed

DENIAU B, Asakage A, Mebazaa A
Clonal haematopoiesis mutations in cardiogenic shock: a beginning of a new era?
Eur J Heart Fail. 2022;24:1583-1585.
PubMed

BURTON JO, Coats AJS, Kovesdy CP, Palmer BF, et al
An international Delphi consensus regarding best practice recommendations for hyperkalaemia across the cardiorenal spectrum.
Eur J Heart Fail. 2022;24:1467-1477.
PubMed Abstract available

CHACKO L, Karia N, Venneri L, Bandera F, et al
Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis.
Eur J Heart Fail. 2022;24:1700-1712.
PubMed Abstract available

HOEVELMANN J, Engel ME, Muller E, Hohlfeld A, et al
A global perspective on the management and outcomes of peripartum cardiomyopathy: a systematic review and meta-analysis.
Eur J Heart Fail. 2022;24:1719-1736.
PubMed Abstract available

ANTONOPOULOS AS, Panagiotopoulos I, Kouroutzoglou A, Koutsis G, et al
Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis.
Eur J Heart Fail. 2022;24:1677-1696.
PubMed Abstract available

SCOLARI FL, Abelson S, Brahmbhatt DH, Medeiros JJF, et al
Clonal haematopoiesis is associated with higher mortality in patients with cardiogenic shock.
Eur J Heart Fail. 2022;24:1573-1582.
PubMed Abstract available

August 2022

NUNEZ J, de la Espriella R, Rossignol P, Voors AA, et al
Congestion in Heart Failure: a circulating biomarker-based perspective.
Eur J Heart Fail. 2022 Aug 30. doi: 10.1002/ejhf.2664.
PubMed Abstract available

PATEL HC, Kaye DM
The rise of devices in heart failure with preserved ejection fraction: the future is not set.
Eur J Heart Fail. 2022 Aug 29. doi: 10.1002/ejhf.2667.
PubMed

NAITO R, Kasai T
Obstructive coronary artery disease, a common and curable but critical comorbidity in acute decompensated heart failure.
Eur J Heart Fail. 2022 Aug 29. doi: 10.1002/ejhf.2665.
PubMed

DOEHNER W, Packer M
Sodium-glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction - lessons from clinical trials. Letter regarding the article 'Dapagliflozin reduces uric acid concentration, an ind
Eur J Heart Fail. 2022 Aug 29. doi: 10.1002/ejhf.2666.
PubMed

SINAGRA G, Paldino A, Dal Ferro M
HEART FAILURE WITH SUPRA-NORMAL LEFT VENTRICLE EJECTION FRACTION: DISTINCT POLYGENIC BASES OF AN UNRECOGNIZED PHENOTYPE.
Eur J Heart Fail. 2022 Aug 23. doi: 10.1002/ejhf.2657.
PubMed

ZITO A, Princi G, Romiti GF, Galli M, et al
Device-based remote monitoring strategies for congestion-guided management of patients with heart failure: a systematic review and meta-analysis.
Eur J Heart Fail. 2022 Aug 23. doi: 10.1002/ejhf.2655.
PubMed Abstract available

ASSMUS B, Angermann CE, Alkhlout B, Asselbergs FW, et al
Effects of remote haemodynamic-guided heart failure management in patients with different subtypes of pulmonary hypertension: Insights from the MEMS-HF study.
Eur J Heart Fail. 2022 Aug 23. doi: 10.1002/ejhf.2656.
PubMed Abstract available

MARTENS P, Chen HH, Verbrugge FH, Testani JT, et al
Assessing Intrinsic Renal Sodium Avidity in Acute Heart Failure: Implications in Predicting and Guiding Decongestion.
Eur J Heart Fail. 2022 Aug 23. doi: 10.1002/ejhf.2662.
PubMed Abstract available

CAI A, Qiu W, Zhou Y, Feng Y, et al
Clinical characteristics and 1-year outcomes in hospitalized patients with heart failure with preserved ejection fraction: Results from the China Cardiovascular Association Database-Heart Failure Center Registry.
Eur J Heart Fail. 2022 Aug 23. doi: 10.1002/ejhf.2654.
PubMed Abstract available

FERREIRA JP, Sharma A, Vasques-Novoa F, Angelico-Goncalves A, et al
Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes.
Eur J Heart Fail. 2022 Aug 23. doi: 10.1002/ejhf.2660.
PubMed Abstract available

OSTROMINSKI JW, Vaduganathan M, Claggett BL, de Boer RA, et al
Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.
Eur J Heart Fail. 2022 Aug 11. doi: 10.1002/ejhf.2652.
PubMed Abstract available

RICHARDS AM
Optimizing the diagnostic utility of NT-proBNP for acute heart failure in obesity and beyond.
Eur J Heart Fail. 2022 Aug 9. doi: 10.1002/ejhf.2653.
PubMed

ADAMSON C, Cowan LM, de Boer RA, Diez M, et al
Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF.
Eur J Heart Fail. 2022 Aug 6. doi: 10.1002/ejhf.2649.
PubMed Abstract available

DE LA ESPRIELLA R, Amiguet M, Minana G, Rodriguez JC, et al
Bending oxygen saturation index and risk of worsening heart failure events in chronic heart failure.
Eur J Heart Fail. 2022 Aug 6. doi: 10.1002/ejhf.2651.
PubMed Abstract available

ANTOHI LE, Adamo M, Chioncel O
Long-term Survival after Acute Heart Failure Hospitalization; From Observation to Collaborative Interventions.
Eur J Heart Fail. 2022 Aug 2. doi: 10.1002/ejhf.2645.
PubMed

LINDBERG F, Lund LH, Benson L, Dahlstrom U, et al
Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry.
Eur J Heart Fail. 2022 Aug 2. doi: 10.1002/ejhf.2644.
PubMed Abstract available

TOMASONI D, Adamo M, Metra M
August 2022 at a glance: focus on heart failure with preserved ejection fraction and cardiac amyloidosis.
Eur J Heart Fail. 2022;24:1325-1326.
PubMed

CHANDRAMOULI C, Lam CSP
Sex, fat and the heart: it's all in the waist.
Eur J Heart Fail. 2022;24:1371-1376.
PubMed

RUBIO-INFANTE N, Ramirez-Flores YA, Castillo EC, Lozano O, et al
Methodological and reporting issues for meta-analysis of immune checkpoint inhibitor-associated cardiotoxicity. Letter regarding the article 'Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis'. Reply.
Eur J Heart Fail. 2022;24:1450-1451.
PubMed

CLEMMENSEN TS, Poulsen SH
Systemic embolism in transthyretin amyloid cardiomyopathy: how to look into the future.
Eur J Heart Fail. 2022;24:1397-1399.
PubMed

VILCHES S, Fontana M, Gonzalez-Lopez E, Mitrani L, et al
Systemic embolism in amyloid transthyretin cardiomyopathy.
Eur J Heart Fail. 2022;24:1387-1396.
PubMed Abstract available

JERING KS, Campagnari C, Claggett B, Adler E, et al
Improving clinical trial efficiency using a machine learning-based risk score to enrich study populations.
Eur J Heart Fail. 2022;24:1418-1426.
PubMed Abstract available

MERLO M, Pagura L, Porcari A, Cameli M, et al
Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey.
Eur J Heart Fail. 2022;24:1377-1386.
PubMed Abstract available

July 2022

BORIANI G, Vitolo M, Imberti JF
Effectiveness of atrial fibrillation ablation in heart failure across the entire spectrum of left ventricular ejection fraction.
Eur J Heart Fail. 2022 Jul 29. doi: 10.1002/ejhf.2642.
PubMed

CHATUR S, Vaduganathan M, Peikert A, Claggett BL, et al
Longitudinal Trajectories in Renal Function Before and After Heart Failure Hospitalization Among Patients with HFpEF in the PARAGON-HF Trial.
Eur J Heart Fail. 2022 Jul 27. doi: 10.1002/ejhf.2638.
PubMed Abstract available

METRA M, Jankowska EA, Pagnesi M, Anker SD, et al
Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial.
Eur J Heart Fail. 2022 Jul 23. doi: 10.1002/ejhf.2630.
PubMed

VADUGANATHAN M, Ferreira JP, Rossignol P, Neuen B, et al
Effects of Steroidal Mineralocorticoid Receptor Antagonists on Acute and Chronic Estimated Glomerular Filtration Rate Slopes in Patients with Chronic Heart Failure.
Eur J Heart Fail. 2022 Jul 22. doi: 10.1002/ejhf.2635.
PubMed Abstract available

SALAH HM, Fudim M
Tolerability and Safety Barriers of SGLT2 Inhibitors Initiation in Heart Failure with Reduced Ejection Fraction.
Eur J Heart Fail. 2022 Jul 22. doi: 10.1002/ejhf.2633.
PubMed

BROMAGE DI, Cannata A, McDonagh TA
Combination diuretic therapy for acute heart failure: "Alone we can do so little; together we can do so much".
Eur J Heart Fail. 2022 Jul 22. doi: 10.1002/ejhf.2634.
PubMed

METRA M, Chioncel O, Cotter G, Davison B, et al
Safety and Efficacy of Istaroxime for Patients with Acute-Heart-Failure-Related Pre-cardiogenic Shock - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study (SEISMiC).
Eur J Heart Fail. 2022 Jul 22. doi: 10.1002/ejhf.2629.
PubMed Abstract available

CARAVITA S, Faini A, Vignati C, Pelucchi S, et al
Intravenous iron therapy improves the hypercapnic ventilatory response and sleep disordered breathing in chronic heart failure.
Eur J Heart Fail. 2022 Jul 22. doi: 10.1002/ejhf.2628.
PubMed Abstract available

LINDE C, Grabowski M, Ponikowski P, Rao I, et al
Cardiac Contractility Modulation Therapy Improves Health Status in Patients with Heart Failure with Preserved Ejection Fraction; a Pilot Study (CCM-HFpEF).
Eur J Heart Fail. 2022 Jul 20. doi: 10.1002/ejhf.2619.
PubMed Abstract available

TOMASONI D, Aimo A, Merlo M, Nardi M, et al
Value of the HFA-PEFF and H2 FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis.
Eur J Heart Fail. 2022 Jul 20. doi: 10.1002/ejhf.2616.
PubMed Abstract available

PAPALIA F, Charles-Edwards G, Okonko DO
Reply to the letter regarding the article "Cardiac Energetics in Patients with Chronic Heart Failure and Iron Deficiency: An in-vivo 31P Magnetic Resonance Study".
Eur J Heart Fail. 2022 Jul 19. doi: 10.1002/ejhf.2625.
PubMed

DANDEL M, Hetzer R
Particular Challenges in the Use of Pulmonary Vasodilating Therapy for Patients with Pulmonary Hypertension Secondary to Left Heart Diseases.
Eur J Heart Fail. 2022 Jul 19. doi: 10.1002/ejhf.2622.
PubMed

GENTILE F, Passino C, Emdin M, Giannoni A, et al
Baroreflex activation therapy in heart failure: targeting the right patient.
Eur J Heart Fail. 2022 Jul 19. doi: 10.1002/ejhf.2627.
PubMed

REDDY YNV, Sundaram V
Spironolactone, fibrosis and heart failure with preserved ejection fraction.
Eur J Heart Fail. 2022 Jul 19. doi: 10.1002/ejhf.2626.
PubMed

KRISTENSEN SL, Gustafsson F
Advanced Heart Failure: time to screen?
Eur J Heart Fail. 2022 Jul 18. doi: 10.1002/ejhf.2624.
PubMed

JANSE RJ, Fu EL, Dahlstrom U, Benson L, et al
Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence.
Eur J Heart Fail. 2022 Jul 18. doi: 10.1002/ejhf.2620.
PubMed Abstract available

CHUNAWALA ZS, Qamar A, Arora S, Pandey A, et al
Prognostic significance of obstructive coronary artery disease in patients admitted with acute decompensated heart failure: The ARIC study community surveillance.
Eur J Heart Fail. 2022 Jul 18. doi: 10.1002/ejhf.2617.
PubMed Abstract available

KOZHUHAROV N, Martin J, Wussler D, Lopez-Ayala P, et al
Clinical Effect of Obesity on NT-proBNP Cut-off Concentrations for the Diagnosis of Acute Heart Failure.
Eur J Heart Fail. 2022 Jul 18. doi: 10.1002/ejhf.2618.
PubMed Abstract available

POCOCK SJ, Ferreira JP, Packer M, Zannad F, et al
Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
Eur J Heart Fail. 2022 Jul 7. doi: 10.1002/ejhf.2607.
PubMed Abstract available

MERKELY B, Geller L, Zima E, Osztheimer I, et al
Baseline clinical characteristics of heart failure patients with reduced ejection fraction enrolled in the BUDAPEST-CRT Upgrade trial.
Eur J Heart Fail. 2022 Jul 5. doi: 10.1002/ejhf.2609.
PubMed Abstract available

SENNI M, Alemayehu WG, Sim D, Edelmann F, et al
Efficacy and Safety of Vericiguat in Patients with Heart Failure with Reduced Ejection Fraction Treated with Sacubitril/Valsartan: Insights from the VICTORIA Trial.
Eur J Heart Fail. 2022 Jul 5. doi: 10.1002/ejhf.2608.
PubMed Abstract available

WANG X, Cunningham JW
Restoring Balance in Heart Failure with Preserved Ejection Fraction.
Eur J Heart Fail. 2022 Jul 5. doi: 10.1002/ejhf.2599.
PubMed

KRISTENSEN SL, Barasa A, Thune JJ
The Challenge of Addressing Heart Failure in Low and Middle Income Countries.
Eur J Heart Fail. 2022 Jul 4. doi: 10.1002/ejhf.2598.
PubMed

BAYES-GENIS A, Aimo A, Lupon J
Empagliflozin in heart failure with preserved and mildly reduced ejection fraction: prognostic benefit confirmed with different endpoint definitions.
Eur J Heart Fail. 2022 Jul 4. doi: 10.1002/ejhf.2597.
PubMed

GULIZIA MM, Orso F, Mortara A, Lucci D, et al
BLITZ-HF: a nationwide initiative to evaluate and improve adherence to acute and chronic heart failure guidelines.
Eur J Heart Fail. 2022 Jul 3. doi: 10.1002/ejhf.2605.
PubMed Abstract available

VON OLSHAUSEN G, Benson L, Dahlstrom U, Lund LH, et al
Catheter Ablation for Patients with Atrial Fibrillation and Heart Failure: Insights from the Swedish Heart Failure Registry.
Eur J Heart Fail. 2022 Jul 2. doi: 10.1002/ejhf.2604.
PubMed Abstract available

VRTOVEC B, Frljak S, Poglajen G, Zemljic G, et al
A PILOT CLINICAL TRIAL OF CELL THERAPY IN HEART FAILURE WITH PRESERVED EJECTION FRACTION.
Eur J Heart Fail. 2022 Jul 1. doi: 10.1002/ejhf.2596.
PubMed Abstract available

MARCO GUAZZI M, Wilhelm M, Halle M, Van Craenenbroeck E, et al
Exercise Testing in HFpEF: an Appraisal Through Diagnosis, Pathophysiology and Therapy A Clinical Consensus Statement of the Heart Failure Association (HFA) and European Association of Preventive Cardiology (EAPC) of the European Society of Cardiology
Eur J Heart Fail. 2022 Jul 1. doi: 10.1002/ejhf.2601.
PubMed Abstract available

Abstracts of the Heart Failure 2022 and the World Congress on Acute Heart Failure, 21 - 24 May 2022, Madrid, Spain.
Eur J Heart Fail. 2022;24 Suppl 2:3-282.
PubMed

TOMASONI D, Adamo M, Metra M
July 2022 at a glance: focus on prognosis, devices and valvular heart disease.
Eur J Heart Fail. 2022;24:1145-1147.
PubMed

SCHRAGE B, Westermann D
Enough iron in transcatheter aortic valve implantation already.
Eur J Heart Fail. 2022;24:1280-1281.
PubMed

DOMINGUEZ F
Predicting pacemaker implantation in cardiac amyloidosis: let's start with an ECG.
Eur J Heart Fail. 2022;24:1237-1238.
PubMed

MCGURK KA, Halliday BP
Dilated cardiomyopathy - details make the difference.
Eur J Heart Fail. 2022;24:1197-1199.
PubMed

PETUTSCHNIGG J, Edelmann F
Closing the gap, or the beauty of alleviating our patients' symptoms.
Eur J Heart Fail. 2022;24:1302-1304.
PubMed

BORIANI G, Vitolo M, Leyva F
Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death: what are the barriers to implementation in the 'real world'?
Eur J Heart Fail. 2022;24:1223-1226.
PubMed

NAYAK A, Mehra MR
Global challenges in left ventricular assist device therapy: a tale across two continents.
Eur J Heart Fail. 2022;24:1316-1318.
PubMed

ILIADIS C, Kalbacher D, Lurz P, Petrescu AM, et al
Left atrial volume index and outcome after transcatheter edge-to-edge valve repair for secondary mitral regurgitation.
Eur J Heart Fail. 2022;24:1282-1292.
PubMed Abstract available

KVASLERUD AB, Bardan S, Andresen K, Klove SF, et al
Intravenous iron supplement for iron deficiency in patients with severe aortic stenosis scheduled for transcatheter aortic valve implantation: results of the IIISAS randomised trial.
Eur J Heart Fail. 2022;24:1269-1279.
PubMed Abstract available

PORCARI A, Rossi M, Cappelli F, Canepa M, et al
Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis.
Eur J Heart Fail. 2022;24:1227-1236.
PubMed Abstract available

JAKUS N, Brugts JJ, Claggett B, Timmermans P, et al
Improved survival of left ventricular assist device carriers in Europe according to implantation eras: results from the PCHF-VAD registry.
Eur J Heart Fail. 2022;24:1305-1315.
PubMed Abstract available

MIRELIS JG, Escobar-Lopez L, Ochoa JP, Espinosa MA, et al
Combination of late gadolinium enhancement and genotype improves prediction of prognosis in non-ischaemic dilated cardiomyopathy.
Eur J Heart Fail. 2022;24:1183-1196.
PubMed Abstract available

MANCA P, Stolfo D, Merlo M, Gregorio C, et al
Transient versus persistent improved ejection fraction in non-ischaemic dilated cardiomyopathy.
Eur J Heart Fail. 2022;24:1171-1179.
PubMed Abstract available

STOCKER TJ, Cohen DJ, Arnold SV, Sommer S, et al
Durability of benefit after transcatheter tricuspid valve intervention: insights from actigraphy.
Eur J Heart Fail. 2022;24:1293-1301.
PubMed Abstract available

June 2022

ABDELHAMID M, Rosano G, Metra M, Adamopoulos S, et al
Prevention of sudden death in heart failure with reduced ejection fraction: Do we still need ICD for primary prevention?
Eur J Heart Fail. 2022 Jun 26. doi: 10.1002/ejhf.2594.
PubMed Abstract available

HARIHARAPUTHIRAN S, Peng Y, Ngo L, Ali A, et al
Long-term Survival and Life Expectancy Following an Acute Heart Failure Hospitalisation in Australia and New Zealand.
Eur J Heart Fail. 2022 Jun 24. doi: 10.1002/ejhf.2595.
PubMed Abstract available

INCIARDI RM, Pagnesi M, Lombardi CM, Anker SD, et al
Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure.
Eur J Heart Fail. 2022 Jun 24. doi: 10.1002/ejhf.2593.
PubMed Abstract available

MULLENS W, Dauw J, Martens P, Meekers E, et al
Acetazolamide in Decompensated Heart Failure with Volume Overload trial (ADVOR): Baseline Characteristics.
Eur J Heart Fail. 2022 Jun 22. doi: 10.1002/ejhf.2587.
PubMed Abstract available

VUKADINOVIC D, Abdin A, Anker SD, Rosano GM, et al
Side effects and treatment initiation barriers of SGLT2 inhibitors in heart failure: A systematic review and meta-analysis.
Eur J Heart Fail. 2022 Jun 22. doi: 10.1002/ejhf.2584.
PubMed Abstract available

RYAN M, Perera D, Petrie MC
Revascularization and heart failure with preserved ejection fraction - time for randomized trials.
Eur J Heart Fail. 2022 Jun 21. doi: 10.1002/ejhf.2583.
PubMed

REDDY YNV
Moving beyond the Vasodilator Model in Heart Failure with reduced Ejection Fraction - Lessons from Sildenafil.
Eur J Heart Fail. 2022 Jun 19. doi: 10.1002/ejhf.2582.
PubMed

AIMO A, Castiglione V, Bayes-Genis A
Do we need to EVALUATE multiple biomarkers and/or the same biomarkers multiple times in patients with heart failure?
Eur J Heart Fail. 2022 Jun 19. doi: 10.1002/ejhf.2580.
PubMed

COATS A, Abraham WT, Zile MR, Lindenfeld JA, et al
Baroreflex activation therapy with the barostim device in patients with heart failure with reduced ejection fraction: A patient level meta-analysis of randomized controlled trials.
Eur J Heart Fail. 2022 Jun 17. doi: 10.1002/ejhf.2573.
PubMed Abstract available

KOBAYASHI M, Girerd N, Ferreira JP, Kevin D, et al
The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial.
Eur J Heart Fail. 2022 Jun 15. doi: 10.1002/ejhf.2579.
PubMed Abstract available

BURRAGE MK, Valkovic L, Rider OJ
Letter regarding the article "Cardiac Energetics in Patients with Chronic Heart Failure and Iron Deficiency: An in-vivo 31P Magnetic Resonance Study".
Eur J Heart Fail. 2022 Jun 15. doi: 10.1002/ejhf.2574.
PubMed

SEFEROVIC P, Farmakis D, Bayes-Genis A, Ben Gal T, et al
Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: A position statement from the Heart Failure Association of the European Society of Cardiology.
Eur J Heart Fail. 2022 Jun 15. doi: 10.1002/ejhf.2575.
PubMed Abstract available

LUND LH, Pitt B, Metra M
Left ventricular ejection fraction as the primary heart failure phenotyping parameter.
Eur J Heart Fail. 2022 Jun 15. doi: 10.1002/ejhf.2576.
PubMed

INCIARDI RM, Chandra A
Epicardial Adipose Tissue in Heart Failure: Risk Factor or Mediator?
Eur J Heart Fail. 2022 Jun 15. doi: 10.1002/ejhf.2577.
PubMed

BHATT AS, Vaduganathan M, Solomon SD, Schneeweiss S, et al
Sacubitril/Valsartan Use Patterns among Older Adults with Heart Failure in Clinical Practice: A Population-Based Cohort Study of >25,000 Medicare Beneficiaries.
Eur J Heart Fail. 2022 Jun 11. doi: 10.1002/ejhf.2572.
PubMed Abstract available

RAGAVAN A, Hogan J, Halliday BP
The spectrum of heart failure with improved ejection fraction - persistent congestion, to heart failure remission and perhaps recovery?
Eur J Heart Fail. 2022 Jun 6. doi: 10.1002/ejhf.2571.
PubMed

HAVAKUK O, Topilsky Y
The Impact of Early Surgery on Mortality in Infective Endocarditis Complicated by Heart Failure - How Much More Data Do We Need?
Eur J Heart Fail. 2022 Jun 1. doi: 10.1002/ejhf.2567.
PubMed

TOMASONI D, Adamo M, Metra M
June 2022 at a glance: prevention, outcomes and treatment.
Eur J Heart Fail. 2022;24:913-915.
PubMed

LEYVA F, Boriani G
The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: insights from an individual patient data meta-analysis of COMPANION and CARE-HF.
Eur J Heart Fail. 2022;24:1091-1093.
PubMed

COOPER LT JR
Sex and autoimmunity in acute myocarditis: time for a refresh.
Eur J Heart Fail. 2022;24:1045-1046.
PubMed

CLELAND JGF, Bristow MR, Freemantle N, Olshansky B, et al
The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta-analysis of COMPANION and CARE-HF.
Eur J Heart Fail. 2022;24:1080-1090.
PubMed Abstract available

YAMAMOTO M, Tajiri K, Ayuzawa S, Ieda M, et al
Pathological findings of clinically suspected myocarditis temporally associated with COVID-19 vaccination.
Eur J Heart Fail. 2022;24:1132-1138.
PubMed Abstract available

BARITUSSIO A, Schiavo A, Basso C, Giordani AS, et al
Predictors of relapse, death or heart transplantation in myocarditis before the introduction of immunosuppression: negative prognostic impact of female gender, fulminant onset, lower ejection fraction and serum autoantibodies.
Eur J Heart Fail. 2022;24:1033-1044.
PubMed Abstract available

GONZALEZ A, Richards AM, de Boer RA, Thum T, et al
Cardiac remodelling - Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology.
Eur J Heart Fail. 2022;24:927-943.
PubMed Abstract available

MARTENS P, Dupont M, Dauw J, Nijst P, et al
The effect of intravenous ferric carboxymaltose on right ventricular function - insights from the IRON-CRT trial.
Eur J Heart Fail. 2022;24:1106-1113.
PubMed Abstract available

CHIANG CH, Chiang CH, Chiang CH
Methodological and reporting issues for meta-analysis of immune checkpoint inhibitor-associated cardiotoxicity. Letter regarding the article 'Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis'.
Eur J Heart Fail. 2022;24:1142-1143.
PubMed

MCDOWELL K, Welsh P, Docherty KF, Morrow DA, et al
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF.
Eur J Heart Fail. 2022;24:1066-1076.
PubMed Abstract available

May 2022

Corrigendum to 'A population-based study of 92 clinicallyrecognized risk factors for heart failure: co-occurrence, prognosis and preventive potential' [Eur J Heart Fail 2022;24:466-480].
Eur J Heart Fail. 2022 May 23. doi: 10.1002/ejhf.2544.
PubMed

ANKER SD, Siddiqi TJ, Filippatos G, Zannad F, et al
Outcomes with Empagliflozin in Heart Failure with Preserved Ejection Fraction Using DELIVER-like Endpoint Definitions.
Eur J Heart Fail. 2022 May 23. doi: 10.1002/ejhf.2558.
PubMed Abstract available

PALAU P, Amiguet M, Dominguez E, Sastre C, et al
Short-term Effects of Dapagliflozin on Maximal Functional Capacity in Heart Failure with Reduced Ejection Fraction (DAPA-VO2 ): A Randomized Clinical Trial.
Eur J Heart Fail. 2022 May 23. doi: 10.1002/ejhf.2560.
PubMed Abstract available

PAGNESI M, Lombardi CM, Chiarito M, Stolfo D, et al
Prognostic impact of the updated 2018 HFA-ESC definition of advanced heart failure: Results from the HELP-HF Registry.
Eur J Heart Fail. 2022 May 23. doi: 10.1002/ejhf.2561.
PubMed Abstract available

SORIMACHI H, Omote K, Omar M, Popovic D, et al
Sex and Central Obesity in Heart Failure with Preserved Ejection Fraction.
Eur J Heart Fail. 2022 May 22. doi: 10.1002/ejhf.2563.
PubMed Abstract available

INCIARDI RM, Bonelli A, Biering-Sorensen T, Cameli M, et al
Left atrial disease and left atrial reverse remodeling across different stages of heart failure development and progression: a new target for prevention and treatment.
Eur J Heart Fail. 2022 May 22. doi: 10.1002/ejhf.2562.
PubMed Abstract available

FUDIM M, Fail PS, Litwin SE, Shaburishvili T, et al
Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: Early Results of the REBALANCE-HF Trial Roll-in Cohort.
Eur J Heart Fail. 2022 May 22. doi: 10.1002/ejhf.2559.
PubMed Abstract available

COOPER TJ, Cleland JG, Guazzi M, Pellicori P, et al
Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (The SilHF study): A randomised placebo-controlled multicentre trial.
Eur J Heart Fail. 2022 May 21. doi: 10.1002/ejhf.2527.
PubMed Abstract available

RAVERA A, Santema BT, de Boer RA, Anker SD, et al
Distinct pathophysiological pathways in women and men with heart failure.
Eur J Heart Fail. 2022 May 21. doi: 10.1002/ejhf.2534.
PubMed Abstract available

JANUS SE, Hajjari J, Chami T, Mously H, et al
Multi-Variable Biomarker Approach in Identifying Incident Heart Failure in Chronic Kidney Disease Results from the Chronic Renal Insufficiency Cohort (CRIC) Study.
Eur J Heart Fail. 2022 May 19. doi: 10.1002/ejhf.2543.
PubMed Abstract available

BAYES-GENIS A, Aimo A, Metra M, Anker S, et al
Head-to-head comparison between recommendations by the ESC and ACC/AHA/HFSA Heart Failure Guidelines.
Eur J Heart Fail. 2022 May 17. doi: 10.1002/ejhf.2542.
PubMed Abstract available

JOHANSSON I, Balasubramanian K, Bangdiwala S, Mielniczuk L, et al
Factors associated with health-related quality of life in heart failure in 23,000 patients from 40 countries: Results of the G-CHF Research Program.
Eur J Heart Fail. 2022 May 15. doi: 10.1002/ejhf.2535.
PubMed Abstract available

NATH M, Romaine SP, Koekemoer A, Hamby S, et al
Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure.
Eur J Heart Fail. 2022 May 15. doi: 10.1002/ejhf.2540.
PubMed Abstract available

VAN ESSEN B, Voors AA, Tromp J
Risk factors for the development of heart failure in patients with or without prior myocardial infarction.
Eur J Heart Fail. 2022 May 12. doi: 10.1002/ejhf.2538.
PubMed

ASLEH R, Briasoulis A, Borlaug BA
Nonsteroidal Aldosterone Receptor Antagonism: A "Fine" Treatment for Heart Failure Patients?
Eur J Heart Fail. 2022 May 12. doi: 10.1002/ejhf.2537.
PubMed

DAMMAN K
When two worlds collide - Making sense of changes in renal function with life saving heart failure therapies.
Eur J Heart Fail. 2022 May 12. doi: 10.1002/ejhf.2539.
PubMed

MYHRE PL, Claggett BL, Shah AM, Prescott MF, et al
Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in heart failure with reduced ejection fraction: the EVALUATE-HF trial.
Eur J Heart Fail. 2022 May 12. doi: 10.1002/ejhf.2541.
PubMed Abstract available

BOHBOT Y, Habib G, Laroche C, Stohr E, et al
Characteristics, management, and outcomes of patients with left-sided infective endocarditis complicated by heart failure: A substudy of the ESC-EORP EURO-ENDO (European infective endocarditis) registry.
Eur J Heart Fail. 2022 May 4. doi: 10.1002/ejhf.2525.
PubMed Abstract available

SCHRAGE B, Lund LH, Benson L, Dahlstrom U, et al
Predictors of primary prevention implantable cardioverter defibrillator use in heart failure with reduced ejection fraction: Impact of the predicted risk of sudden cardiac death and all-cause mortality.
Eur J Heart Fail. 2022 May 3. doi: 10.1002/ejhf.2530.
PubMed Abstract available

ERQOU S, Adler AI, Challa AA, Fonarow GC, et al
Insulin Resistance and Incident Heart Failure: A Meta-Analysis.
Eur J Heart Fail. 2022 May 3. doi: 10.1002/ejhf.2531.
PubMed

TOMASONI D, Adamo M, Metra M
May 2022 at a glance. Focus on treatment: from epidemiologic data to randomized trials and new devices.
Eur J Heart Fail. 2022;24:735-737.
PubMed

COATS AJS
What's all the fuss about a new guideline?
Eur J Heart Fail. 2022;24:743-745.
PubMed

SORAJJA P, Cavalcante J, Bapat V
Setting expectations for transcatheter mitral valve replacement in the real world.
Eur J Heart Fail. 2022;24:908-909.
PubMed

FRERKER C, Karam N, Hahn RT, Thiele H, et al
New ESC/EACTS guideline recommendations for the treatment of secondary mitral regurgitation: reflections on the evidence.
Eur J Heart Fail. 2022;24:746-749.
PubMed

REDDY YNV
Using the ejection fraction to guide medical therapy: a necessary but imperfect first step.
Eur J Heart Fail. 2022;24:779-781.
PubMed

BEN ALI W, Ludwig S, Duncan A, Weimann J, et al
Characteristics and outcomes of patients screened for transcatheter mitral valve implantation: 1-year results from the CHOICE-MI registry.
Eur J Heart Fail. 2022;24:887-898.
PubMed Abstract available

ROSANO GMC, Celant S, Olimpieri PP, Colatrella A, et al
Impact of the COVID-19 pandemic on prescription of sacubitril/valsartan in Italy.
Eur J Heart Fail. 2022;24:855-860.
PubMed Abstract available

BUTLER J, Spertus JA, Bamber L, Khan MS, et al
Defining changes in physical limitation from the patient perspective: insights from the VITALITY-HFpEF randomized trial.
Eur J Heart Fail. 2022;24:843-850.
PubMed Abstract available

WILD MG, Kreidel F, Hell MM, Praz F, et al
Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real-world multicentre experience.
Eur J Heart Fail. 2022;24:899-907.
PubMed Abstract available

April 2022

AIMO A, Vergaro G, Gonzalez A, Barison A, et al
Cardiac Remodelling Part 2: Clinical, Imaging and Laboratory Findings A review from the Biomarkers Working Group of the Heart Failure Association of the ESC.
Eur J Heart Fail. 2022 Apr 30. doi: 10.1002/ejhf.2522.
PubMed Abstract available

CARTER S, Hendren NS, Grodin JL
Sodium-glucose cotransporter 2 inhibition, uric acid, and heart failure: correlation without causation?
Eur J Heart Fail. 2022 Apr 29. doi: 10.1002/ejhf.2516.
PubMed

REZA N, Butler J
Assessing Health Status After Discharge for Decompensated Heart Failure: A Patient-Centered Priority.
Eur J Heart Fail. 2022 Apr 28. doi: 10.1002/ejhf.2521.
PubMed

BORIANI G, Imberti JF, Vitolo M
Dronedarone in the treatment of atrial fibrillation with concomitant heart failure and preserved or mildly reduced ejection fraction: closer to Ithaca after a long Odyssey?
Eur J Heart Fail. 2022 Apr 28. doi: 10.1002/ejhf.2519.
PubMed

PELLICORI P, Cleland JG
Heart failure: age is no excuse for complacency.
Eur J Heart Fail. 2022 Apr 28. doi: 10.1002/ejhf.2517.
PubMed

CANNATA A, Bromage DI, McDonagh TA
COVID and heart failure: the dark side of the moon.
Eur J Heart Fail. 2022 Apr 28. doi: 10.1002/ejhf.2518.
PubMed

KALOGEROPOULOS AP, Tam E
Intravenous iron in heart failure with reduced ejection fraction: just about right.
Eur J Heart Fail. 2022 Apr 28. doi: 10.1002/ejhf.2520.
PubMed

JIN X, Hung CL, Tay WT, Soon D, et al
Epicardial Adipose Tissue related to Left Atrial and Ventricular Function in Heart Failure with Preserved (HFpEF) versus Reduced and Mildly Reduced Ejection Fraction (HFrEF/HFmrEF).
Eur J Heart Fail. 2022 Apr 27. doi: 10.1002/ejhf.2513.
PubMed Abstract available

XIE C
Could angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitor be used in heart failure patients with atrial fibrillation and low blood pressure?
Eur J Heart Fail. 2022 Apr 27. doi: 10.1002/ejhf.2515.
PubMed

EMDIN M, Aimo A, Castiglione V
Is Targeting Cyclic Guanosine Monophosphate by Vericiguat Effective to Treat Ischaemic Heart Failure with Reduced Ejection Fraction? Yes, It Is.
Eur J Heart Fail. 2022 Apr 21. doi: 10.1002/ejhf.2511.
PubMed

STRAW S, Gierula J, Witte KK
Designing clinical trials in heart failure with preserved ejection fraction: quality over quantity?
Eur J Heart Fail. 2022 Apr 21. doi: 10.1002/ejhf.2510.
PubMed

MCNAUGHTON CD, McConnachie A, Cleland JG, Spertus JA, et al
Quality of life assessed six months after hospitalisation for acute heart failure: An analysis from REPORT-HF (International Registry to assess mEdical Practice with lOngitudinal obseRvation for Treatment of Heart Failure).
Eur J Heart Fail. 2022 Apr 16. doi: 10.1002/ejhf.2508.
PubMed Abstract available

GIRERD N, Mewton N, Tartiere JM, Guijarro D, et al
Practical outpatient management of worsening chronic heart failure.
Eur J Heart Fail. 2022 Apr 13. doi: 10.1002/ejhf.2503.
PubMed Abstract available

STEWART COATS AJ
HeartFailureNews Figures of the Heart Failure Association: Professor Finn Gustafsson, Board Member, 2020-2022.
Eur J Heart Fail. 2022 Apr 13. doi: 10.1002/ejhf.2502.
PubMed

KALOGEROPOULOS AP, Butler J
Uptitrating versus adding heart failure with reduced ejection fraction medications: bring more players to the game.
Eur J Heart Fail. 2022 Apr 13. doi: 10.1002/ejhf.2507.
PubMed

STEWART COATS AJ
Figures of the Heart Failure Association: Doctor Amina Rakisheva, Board Member, 2020-2022.
Eur J Heart Fail. 2022 Apr 12. doi: 10.1002/ejhf.2499.
PubMed

ALNUWAYSIR RIS, Grote Beverborg N, van der Meer P
Fluctuating iron levels in heart failure: when and where to look at?
Eur J Heart Fail. 2022 Apr 12. doi: 10.1002/ejhf.2500.
PubMed

VOORDES GHD, Heerspink HJL, Ter Maaten JM
The interplay between sacubitril/valsartan, heart failure with preserved ejection fraction, diabetes and kidney function.
Eur J Heart Fail. 2022 Apr 12. doi: 10.1002/ejhf.2501.
PubMed

SINHA A, Yancy CW, Patel RB
Tipping the scale toward a more accurate and equitable assessment of heart failure with reduced ejection fraction pharmacotherapy eligibility: a call to incorporate cystatin C in estimating glomerular filtration rate.
Eur J Heart Fail. 2022 Apr 12. doi: 10.1002/ejhf.2505.
PubMed

RASTOGI T, Ho FK, Rossignol P, Merkling T, et al
Comparing and contrasting risk factors for Heart failure in patients with and without history of myocardial infarction: Data from HOMAGE and the UK Biobank.
Eur J Heart Fail. 2022 Apr 1. doi: 10.1002/ejhf.2495.
PubMed Abstract available

TOMASONI D, Adamo M, Metra M
April 2022 at a glance: focus on prevention, acute heart failure and heart failure with preserved ejection fraction.
Eur J Heart Fail. 2022;24:593-595.
PubMed

CLELAND JGF, Butler J, Januzzi JL Jr, Pellicori P, et al
Only people with increased plasma concentrations of natriuretic peptides should be included in outcome trials of diabetes, cardiovascular and kidney disease: implications for clinical practice.
Eur J Heart Fail. 2022;24:678-680.
PubMed

GROTE BEVERBORG N
The heart during iron deficiency: a non-rechargeable battery?
Eur J Heart Fail. 2022;24:724-726.
PubMed

TAVAZZI L, Maggioni AP, Rapezzi C, Ferrari R, et al
Clinical trials: conventional or pragmatic?
Eur J Heart Fail. 2022;24:596-599.
PubMed

SIDHU K, Castrini AI, Parikh V, Reza N, et al
The response to cardiac resynchronization therapy in LMNA cardiomyopathy.
Eur J Heart Fail. 2022;24:685-693.
PubMed Abstract available

CHIONCEL O, Adamo M, Bauersachs J
Risk stratification in cardiogenic shock: from clinical utility to improving outcomes.
Eur J Heart Fail. 2022;24:668-671.
PubMed

MARINO PN, Zanaboni J
Does left atrial deformation impact on symptoms and prognosis in functional mitral regurgitation patients with poor left ventricular function?
Eur J Heart Fail. 2022;24:705-707.
PubMed

HOLM H, Magnusson M, Jujic A, Bozec E, et al
How to calculate ventricular-arterial coupling?
Eur J Heart Fail. 2022;24:600-602.
PubMed

HAVAKUK O, Topilsky Y
The interplay between functional mitral regurgitation and left atrial function.
Eur J Heart Fail. 2022;24:703-704.
PubMed

IKONOMIDIS I, Lambadiari V, Mitrakou A, Kountouri A, et al
Myocardial work and vascular dysfunction are partially improved at 12 months after COVID-19 infection.
Eur J Heart Fail. 2022;24:727-729.
PubMed

BEER BN, Jentzer JC, Weimann J, Dabboura S, et al
Early risk stratification in patients with cardiogenic shock irrespective of the underlying cause - the Cardiogenic Shock Score.
Eur J Heart Fail. 2022;24:657-667.
PubMed Abstract available

March 2022

NIJHOLT KT, Westenbrink BD
Reply to letter to the editor regarding the article 'Exercise: a molecular tool to boost muscle growth and mitochondrial performance in heart failure?'
Eur J Heart Fail. 2022 Mar 26. doi: 10.1002/ejhf.2494.
PubMed

ANKER SD, Ponikowski P, Khan MS, Friede T, et al
Responder analysis for improvement in six-minute walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency.
Eur J Heart Fail. 2022 Mar 25. doi: 10.1002/ejhf.2491.
PubMed Abstract available

Corrigendum to 'Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy' [Eur J Heart Fail 2021;23:854-871].
Eur J Heart Fail. 2022 Mar 17. doi: 10.1002/ejhf.2474.
PubMed

DEVORE AD, Hellkamp AS, Thomas L, Albert NM, et al
The Association of Improvement in Left Ventricular Ejection Fraction with Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Data from CHAMP-HF.
Eur J Heart Fail. 2022 Mar 15. doi: 10.1002/ejhf.2486.
PubMed Abstract available

VADUGANATHAN M, Piccini JP, Camm AJ, Crijns HJGM, et al
Dronedarone for the Treatment of Atrial Fibrillation with Concomitant Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Post-Hoc Analysis of the ATHENA Trial.
Eur J Heart Fail. 2022 Mar 15. doi: 10.1002/ejhf.2487.
PubMed Abstract available

KESHVANI N, Mehta A, Alger HM, Rutan C, et al
Heart Failure Quality of Care and In-Hospital Outcomes During the COVID-19 Pandemic Findings from the Get With The Guidelines-Heart Failure Registry.
Eur J Heart Fail. 2022 Mar 14. doi: 10.1002/ejhf.2484.
PubMed Abstract available

BUTLER J, Khan MS, Friede T, Jankowska EA, et al
Health Status Improvement with Ferric Carboxymaltose in Heart Failure with Reduced Ejection Fraction and Iron Deficiency.
Eur J Heart Fail. 2022 Mar 13. doi: 10.1002/ejhf.2478.
PubMed Abstract available

FORREST IS, Rocheleau G, Bafna S, Argulian E, et al
Genetic and phenotypic profiling of supranormal ejection fraction reveals decreased survival and underdiagnosed heart failure.
Eur J Heart Fail. 2022 Mar 12. doi: 10.1002/ejhf.2482.
PubMed Abstract available

STOLFO D, Lund LH, Becher PM, Orsini N, et al
Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata.
Eur J Heart Fail. 2022 Mar 12. doi: 10.1002/ejhf.2483.
PubMed Abstract available

Corrigendum to 'Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study
Eur J Heart Fail. 2022 Mar 10. doi: 10.1002/ejhf.2473.
PubMed

Corrigendum to 'Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry [Eur J Heart Fail 2021;23:1844-1854].
Eur J Heart Fail. 2022 Mar 10. doi: 10.1002/ejhf.2472.
PubMed

D'AMARIO D, Rodolico D, Rosano GM, Dahlstrom U, et al
Association Between Dosing And Combination Use Of Medications And Outcomes In Heart Failure With Reduced Ejection Fraction: Data From The Swedish Heart Failure Registry.
Eur J Heart Fail. 2022 Mar 8. doi: 10.1002/ejhf.2477.
PubMed Abstract available

KONSTAM MA
Autonomic Dysregulation in Diabetes: CAN We Prevent Heart Failure?
Eur J Heart Fail. 2022 Mar 4. doi: 10.1002/ejhf.2476.
PubMed

SALDARRIAGA C, Atar D, Stebbins A, Lewis BS, et al
Vericiguat in Patients with Coronary Artery Disease and Heart Failure with Reduced Ejection Fraction.
Eur J Heart Fail. 2022 Mar 3. doi: 10.1002/ejhf.2468.
PubMed Abstract available

KHAN MS, Shahid I, Fonarow GC, Greene SJ, et al
Classifying Heart Failure Based on Ejection Fraction: Imperfect but Enduring.
Eur J Heart Fail. 2022 Mar 3. doi: 10.1002/ejhf.2470.
PubMed

FILIPPATOS G, Pitt B, Agarwal R, Farmakis D, et al
Finerenone in patients with CKD and T2D with and without heart failure: A prespecified subgroup analysis of the FIDELIO-DKD trial.
Eur J Heart Fail. 2022 Mar 3. doi: 10.1002/ejhf.2469.
PubMed Abstract available

MULLENS W, Martens P, Testani JM, Tang WHW, et al
Renal effects of guideline directed medical therapies in heart failure - a consensus document from the Heart Failure Association of the European Society of Cardiology.
Eur J Heart Fail. 2022 Mar 3. doi: 10.1002/ejhf.2471.
PubMed

KOKHAN E, Kiyakbaev G, Medovchshikov V
Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article "Early benefit with empagliflozin in heart failure with preserved ejecti
Eur J Heart Fail. 2022 Mar 3. doi: 10.1002/ejhf.2466.
PubMed

ANDRIOPOULOU M, Dimaki N, Kallistratos MS, Chamodraka E, et al
Skeletal muscle alterations and exercise intolerance in heart failure with preserved ejection fraction patients: ultrasonography assessment of diaphragm and quadriceps.
Eur J Heart Fail. 2022 Mar 1. doi: 10.1002/ejhf.2462.
PubMed

TOMASONI D, Adamo M, Metra M
March 2022 at a glance: focus on medical therapy, prevention and comorbidities.
Eur J Heart Fail. 2022;24:403-405.
PubMed

DAUW J, Mullens W, Girerd N
The fastest way to the heart is through the veins: towards a better understanding of congestion.
Eur J Heart Fail. 2022;24:463-465.
PubMed

KOEHLER F, Schulz M
The AMULET menage a trois: nurse, telemedicine support, and remote cardiologist.
Eur J Heart Fail. 2022;24:578-580.
PubMed

DE SOUSA C, Pinto FJ
Dapagliflozin post-transcatheter aortic valve implantation: the need for further evidence.
Eur J Heart Fail. 2022;24:589-590.
PubMed

DONAL E, Sade LE, Thomas L
Left atrial function: the HbA1c for the cardiologist and even more.
Eur J Heart Fail. 2022;24:494-496.
PubMed

CURTAIN JP, Jackson AM, Shen L, Jhund PS, et al
Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF.
Eur J Heart Fail. 2022;24:551-561.
PubMed Abstract available

RUSSO G, Taramasso M, Pedicino D, Gennari M, et al
Challenges and future perspectives of transcatheter tricuspid valve interventions: adopt old strategies or adapt to new opportunities?
Eur J Heart Fail. 2022;24:442-454.
PubMed Abstract available

IVEY-MIRANDA JB, Wetterling F, Gaul R, Sheridan S, et al
Changes in inferior vena cava area represent a more sensitive metric than changes in filling pressures during experimental manipulation of intravascular volume and tone.
Eur J Heart Fail. 2022;24:455-462.
PubMed Abstract available

AMAT-SANTOS IJ, Sanchez-Luna JP, Abu-Assi E, Melendo-Viu M, et al
Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial.
Eur J Heart Fail. 2022;24:581-588.
PubMed Abstract available

February 2022

BHATT AS, Fonarow GC, Greene SJ
Prioritizing Prevention of De Novo and Worsening Chronic Heart Failure.
Eur J Heart Fail. 2022 Feb 25. doi: 10.1002/ejhf.2464.
PubMed

KAMBIC T, Piepoli MF, Lainscak M
Exercise intolerance in heart failure: beyond mitochondrial dysfunction.
Eur J Heart Fail. 2022 Feb 25. doi: 10.1002/ejhf.2461.
PubMed

FERREIRA JP, Verdonschot JAJ, Girerd N, Bozec E, et al
Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial.
Eur J Heart Fail. 2022 Feb 23. doi: 10.1002/ejhf.2455.
PubMed Abstract available

BUTT JH, Adamson C, Docherty KF, Vaduganathan M, et al
Eligibility for Pharmacological Therapies in Heart Failure with Reduced Ejection Fraction: Implications of the New CKD-EPI Creatinine Equation for Estimating Glomerular Filtration Rate.
Eur J Heart Fail. 2022 Feb 23. doi: 10.1002/ejhf.2460.
PubMed Abstract available

PAPALIA F, Jouhra F, Amin-Youssef G, Shah AM, et al
Cardiac Energetics in Patients with Chronic Heart Failure and Iron Deficiency: An in-vivo 31P Magnetic Resonance Study.
Eur J Heart Fail. 2022 Feb 23. doi: 10.1002/ejhf.2454.
PubMed Abstract available

FERREIRA JP, Packer M, Butler J, Zannad F, et al
Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure.
Eur J Heart Fail. 2022 Feb 22. doi: 10.1002/ejhf.2457.
PubMed Abstract available

ROSSIGNOL P, Pitt B
Time to Shift our Focus from the Treatment to the Prevention of Heart Failure with a Mineralocorticoid Receptor Antagonist (MRA)?
Eur J Heart Fail. 2022 Feb 21. doi: 10.1002/ejhf.2459.
PubMed

IKONOMIDIS I, Vlastos D
Corrigendum to 'The role of ventricular-arterial coupling in cardiac disease and heart failure: assessment, clinical implications and therapeutic interventions. A consensus document of the European Society of Cardiology Working Group on Aorta & Periph
Eur J Heart Fail. 2022 Feb 9. doi: 10.1002/ejhf.2452.
PubMed

PEIKERT A, Vaduganathan M, McCausland F, Claggett BL, et al
Effects of Sacubitril/Valsartan Versus Valsartan on Renal Function in Patients with and without Diabetes and Heart Failure with Preserved Ejection Fraction: Insights From PARAGON-HF.
Eur J Heart Fail. 2022 Feb 4. doi: 10.1002/ejhf.2450.
PubMed Abstract available

DEO SV, Reddy YN, Zakeri R, Karnib M, et al
Revascularization in Ischemic Heart Failure with Preserved Ejection Fraction: A Nationwide Cohort Study.
Eur J Heart Fail. 2022 Feb 4. doi: 10.1002/ejhf.2446.
PubMed

MOHAMED MO
Prevention is better than cure: modifiable risk factors for heart failure better understood.
Eur J Heart Fail. 2022 Feb 4. doi: 10.1002/ejhf.2448.
PubMed

KONDO T, Jhund PS, McMurray JJV
Drug therapy for heart failure with reduced ejection fraction: what is the 'right' dose?
Eur J Heart Fail. 2022 Feb 4. doi: 10.1002/ejhf.2447.
PubMed Abstract available

VARSHNEY AS, Singh JP, Vaduganathan M
A Heart Team Approach to Contemporary Device Decision-Making in Heart Failure.
Eur J Heart Fail. 2022 Feb 3. doi: 10.1002/ejhf.2445.
PubMed

PITT B, Epstein M
A Promise Unfulfilled : The use of Mineralocorticoid Receptor Antagonists ( MRAs ) in patients with Heart Failure and a Reduced Left Ventricular Ejection Fraction.
Eur J Heart Fail. 2022 Feb 3. doi: 10.1002/ejhf.2441.
PubMed

ARITA VA, Van Veldhuisen DJ, Rienstra M
Dapagliflozin effect on heart failure with prevalent or new-onset atrial fibrillation.
Eur J Heart Fail. 2022 Feb 3. doi: 10.1002/ejhf.2443.
PubMed

EL-BATTRAWY I, Akin I
Impact of sacubitril/valsartan on cardiac arrest event rate. Letter regarding the article 'Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baselin
Eur J Heart Fail. 2022 Feb 3. doi: 10.1002/ejhf.2444.
PubMed

OMAR M, Jensen MD, Borlaug BA
Diabesity and heart failure with preserved ejection fraction: the picture is getting clearer.
Eur J Heart Fail. 2022 Feb 3. doi: 10.1002/ejhf.2440.
PubMed

HFA Winter Meeting on Translational Heart Failure Research 27-28 January 2022.
Eur J Heart Fail. 2022;24 Suppl 1:3-12.
PubMed

TOMASONI D, Adamo M, Metra M
February 2022 at a glance: focus on pathophysiology and acute heart failure.
Eur J Heart Fail. 2022;24:243-244.
PubMed

TREVISAN M, Fu EL, Carrero JJ
Reply to the letter regarding the article 'Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care'.
Eur J Heart Fail. 2022;24:399-400.
PubMed

WARRAICH HJ, Nohria A
Is worsening renal function relevant without clinical context?
Eur J Heart Fail. 2022;24:375-377.
PubMed

FACILE A, Mewton N, Nguon M, Durand de Gevigney G, et al
Primary endpoint adjudication: comparison between the expert committee and the regulatory MedDRA(R) coding in the MITRA-FR study.
Eur J Heart Fail. 2022;24:396-398.
PubMed

ALEXANDROU ME, Sarafidis PA
Letter regarding the article 'Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care'.
Eur J Heart Fail. 2022;24:399.
PubMed

OBOKATA M, Reddy YNV, Melenovsky V, Sorimachi H, et al
Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity.
Eur J Heart Fail. 2022;24:353-361.
PubMed Abstract available

January 2022

PABON MA, Cunningham JW, Claggett BL, Packer M, et al
Natriuretic Peptide-Based Inclusion Criteria in Heart Failure with Preserved Ejection Fraction Clinical Trials: Insights from PARAGON-HF.
Eur J Heart Fail. 2022 Jan 26. doi: 10.1002/ejhf.2439.
PubMed Abstract available

KAZE AD, Yuyun MF, Erqou S, Fonarow GC, et al
Cardiac Autonomic Neuropathy and Risk of Incident Heart Failure Among Adults with Type 2 Diabetes.
Eur J Heart Fail. 2022 Jan 22. doi: 10.1002/ejhf.2432.
PubMed Abstract available

TROMP J, Beusekamp JC, Ouwerkerk W, van der Meer P, et al
Regional Differences in Precipitating Factors of Hospitalization for Acute Heart Failure: Insights from the REPORT-HF Registry.
Eur J Heart Fail. 2022 Jan 22. doi: 10.1002/ejhf.2431.
PubMed Abstract available

CHANDRAMOULI C, Ting TW, Tromp J, Agarwal A, et al
Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction.
Eur J Heart Fail. 2022 Jan 21. doi: 10.1002/ejhf.2435.
PubMed Abstract available

MULLENS W, Coats A, Seferovic P, Metra M, et al
Education and Certification on Heart Failure of the Heart Failure Association of the European Society of Cardiology.
Eur J Heart Fail. 2022 Jan 11. doi: 10.1002/ejhf.2430.
PubMed Abstract available

POTTER E, Stephenson G, Harris J, Wright L, et al
Screening-Guided Spironolactone Treatment of Subclinical Left Ventricular Dysfunction for Heart Failure Prevention in At-risk Patients.
Eur J Heart Fail. 2022 Jan 11. doi: 10.1002/ejhf.2428.
PubMed Abstract available

MALAGOLI A, Rossi L, Zanni A, Sticozzi C, et al
Quantified mitral regurgitation and left atrial function in heart failure with reduced ejection fraction: interplay and outcome implications.
Eur J Heart Fail. 2022 Jan 11. doi: 10.1002/ejhf.2429.
PubMed Abstract available

MC CAUSLAND FR, Lefkowitz MP, Claggett B, Packer M, et al
Angiotensin-Neprilysin Inhibition and Renal Outcomes Across the Spectrum of Ejection Fraction in Heart Failure.
Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2421.
PubMed Abstract available

PATEL RB, Shah SJ, Inciardi RM
Collagen Homeostasis of the Left Atrium: An Emerging Treatment Target to Prevent Heart Failure?
Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2422.
PubMed

MADIAS JE
Pathophysiology and therapy of Takotsubo syndrome. Letter regarding the article 'Pathophysiology of Takotsubo syndrome - a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Gro
Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2413.
PubMed

DOUMAS M, Patoulias D, Papadopoulos C
Epicardial adipose tissue: does it mediate the cardio-protective effects of sodium-glucose co-transporter 2 inhibitors in patients with heart failure? Letter regarding the article 'Impact of epicardial adipose tissue on cardiovascular haemodynamics, m
Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2412.
PubMed

CEELEN D, Voors AA, Tromp J, van Veldhuisen DJ, et al
Pathophysiological pathways related to high plasma GDF-15 concentrations in patients with heart failure.
Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2424.
PubMed Abstract available

BUTLER J, Siddiqi TJ, Filippatos G, Ferreira JP, et al
Early Benefit with Empagliflozin in Heart Failure with Preserved Ejection Fraction Insights from the EMPEROR-Preserved Trial.
Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2420.
PubMed Abstract available

DE BIASE N, Del Punta L, Pugliese NR
Reply: Epicardial adipose tissue: does it mediate the cardio-protective effects of SGLT-2 inhibitors in subjects with heart failure?
Eur J Heart Fail. 2022 Jan 5. doi: 10.1002/ejhf.2423.
PubMed

PIEPOLI MF, Adamo M, Barison A, Bestetti RB, et al
Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology.
Eur J Heart Fail. 2022;24:143-168.
PubMed Abstract available

TOMASONI D, Adamo M, Metra M
January 2022 at a glance: time for the new ESC guidelines on heart failure.
Eur J Heart Fail. 2022;24:1-3.
PubMed

MCDONAGH TA, Metra M, Adamo M, Gardner RS, et al
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contri
Eur J Heart Fail. 2022;24:4-131.
PubMed Abstract available

AKTAA S, Polovina M, Rosano G, Abdin A, et al
European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society o
Eur J Heart Fail. 2022;24:132-142.
PubMed Abstract available

ROSENKRANZ S, Channick R, Chin KM, Jenner B, et al
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study.
Eur J Heart Fail. 2022;24:205-214.
PubMed Abstract available

December 2021

ZAHIR D, Bonde A, Madelaire C, Malmborg M, et al
Temporal trends in initiation of mineralocorticoid receptor antagonists and risk of subsequent withdrawal in patients with heart failure: A nationwide study in Denmark from 2003-2017.
Eur J Heart Fail. 2021 Dec 30. doi: 10.1002/ejhf.2418.
PubMed Abstract available

BANERJEE A, Pasea L, Chung SC, Direk K, et al
A population-based study of 92 clinically recognised risk factors for heart failure: co-occurrence, prognosis and preventive potential.
Eur J Heart Fail. 2021 Dec 30. doi: 10.1002/ejhf.2417.
PubMed Abstract available

DE BOER RA, Heymans S, Backs J, Carrier L, et al
Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society o
Eur J Heart Fail. 2021 Dec 30. doi: 10.1002/ejhf.2414.
PubMed Abstract available

MEEMS LMG, van Veldhuisen DJ, de Boer RA
Underestimation of congestion in very obese heart failure with preserved ejection fraction patients: EAT your heart out...?!
Eur J Heart Fail. 2021 Dec 30. doi: 10.1002/ejhf.2415.
PubMed

KAPLON-CIESLICKA A, Benson L, Chioncel O, Crespo-Leiro MG, et al
A comprehensive characterization of acute heart failure with preserved vs. mildly reduced vs. reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry.
Eur J Heart Fail. 2021 Dec 27. doi: 10.1002/ejhf.2408.
PubMed Abstract available

BAYES-GENIS A, Nunez J, Lupon J
Dysglycemia and High Natriuretic Peptides: The Prelude to Heart Failure.
Eur J Heart Fail. 2021 Dec 26. doi: 10.1002/ejhf.2410.
PubMed

NIJHOLT KT, Sanchez-Aguilera PI, Voorrips SN, de Boer RA, et al
Exercise: a molecular tool to boost muscle growth and mitochondrial performance in heart failure?
Eur J Heart Fail. 2021 Dec 26. doi: 10.1002/ejhf.2407.
PubMed Abstract available

FERREIRA JP, Anker SD, Butler J, Filippatos G, et al
Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced.
Eur J Heart Fail. 2021 Dec 26. doi: 10.1002/ejhf.2409.
PubMed Abstract available

AL-MUBARAK AA, Beverborg NG, Suthahar N, Gansevoort RT, et al
High selenium levels associate with reduced risk of mortality and new onset heart failure: data from PREVEND.
Eur J Heart Fail. 2021 Dec 20. doi: 10.1002/ejhf.2405.
PubMed Abstract available

Corrigendum to 'Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials' [Eur J Heart Fail 2020;11:2160-2171].
Eur J Heart Fail. 2021 Dec 20. doi: 10.1002/ejhf.2404.
PubMed

ANDERSEN DM, Sengelov M, Olsen FJ, Marott JL, et al
Measures of Left Atrial Function Predicts Incident Heart Failure in a Low Risk General Population: The Copenhagen City Heart Study.
Eur J Heart Fail. 2021 Dec 20. doi: 10.1002/ejhf.2406.
PubMed Abstract available

JACKSON AM, Rorth R, Liu J, Kristensen SL, et al
Diabetes and prediabetes in patients with heart failure and preserved ejection fraction.
Eur J Heart Fail. 2021 Dec 17. doi: 10.1002/ejhf.2403.
PubMed Abstract available

WEIR RA, Clements S, Steedman T, Dargie HJ, et al
Prognostic value of cardiac magnetic resonance parameters and biomarkers following myocardial infarction; 10 year follow-up of the Eplerenone Remodeling in Myocardial Infarction without Heart Failure trial.
Eur J Heart Fail. 2021 Dec 14. doi: 10.1002/ejhf.2402.
PubMed Abstract available

OMEROVIC E, Citro R, Bossone E, Redfors B, et al
Pathophysiology of Takotsubo Syndrome - a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of Cardiology - Part 1: Overview and the central role
Eur J Heart Fail. 2021 Dec 14. doi: 10.1002/ejhf.2400.
PubMed Abstract available

TOMASONI D, Fonarow GC, Adamo M, Anker SD, et al
Sodium-glucose co-transporter 2 inhibitors as an early, first line therapy in patients with heart failure and reduced ejection fraction.
Eur J Heart Fail. 2021 Dec 10. doi: 10.1002/ejhf.2397.
PubMed Abstract available

PAGNESI M, Butler J, Metra M
Ejection fraction in heart failure: just become Emperor's new clothes?
Eur J Heart Fail. 2021 Dec 10. doi: 10.1002/ejhf.2399.
PubMed

TOMASONI D, Adamo M, Metra M
December 2021 at a glance: focus on medical treatment, valvular heart disease and prognostic models.
Eur J Heart Fail. 2021;23:1993-1994.
PubMed

VAN BERGEIJK KH, Voors AA, Wykrzykowska JJ
Prime time for machine learning to predict clinical outcomes in valvular heart disease?
Eur J Heart Fail. 2021;23:2033-2034.
PubMed

SINAGRA G, Porcari A, Fabris E, Merlo M, et al
Standardizing the role of endomyocardial biopsy in current clinical practice worldwide.
Eur J Heart Fail. 2021;23:1995-1998.
PubMed

VIDULA MK, Orlenko A, Zhao L, Salvador L, et al
Plasma biomarkers associated with adverse outcomes in patients with calcific aortic stenosis.
Eur J Heart Fail. 2021;23:2021-2032.
PubMed Abstract available

STRACHINARU M, Nijveldt R, Vernooy K
Arrhythmic risk management after acute myocarditis: never too early, only too late.
Eur J Heart Fail. 2021;23:2055-2057.
PubMed

HALLIDAY BP, de Marvao A, Thilaganathan B
Peripartum cardiomyopathy and pre-eclampsia: two tips of the same iceberg.
Eur J Heart Fail. 2021;23:2070-2072.
PubMed

GENTILE P, Merlo M, Peretto G, Ammirati E, et al
Post-discharge arrhythmic risk stratification of patients with acute myocarditis and life-threatening ventricular tachyarrhythmias.
Eur J Heart Fail. 2021;23:2045-2054.
PubMed Abstract available

SUZUKI K, Claggett B, Minamisawa M, Packer M, et al
Influence of study discontinuation during the run-in period on the estimated efficacy of sacubitril/valsartan in the PARAGON-HF trial.
Eur J Heart Fail. 2021;23:2085-2090.
PubMed Abstract available

JACKSON AM, Petrie MC, Frogoudaki A, Laroche C, et al
Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry.
Eur J Heart Fail. 2021;23:2058-2069.
PubMed Abstract available

November 2021

RAVASSA S, Lopez B, Ferreira JP, Girerd N, et al
Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling.
Eur J Heart Fail. 2021 Nov 28. doi: 10.1002/ejhf.2394.
PubMed Abstract available

Corrigendum to 'High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality' [Eur J Heart Fail 2021;23:919-932].
Eur J Heart Fail. 2021 Nov 24. doi: 10.1002/ejhf.2383.
PubMed

FAUCHIER L, Bisson A, Lip GYH
Age, sex and clinical outcomes with digoxin vs beta-blocker in permanent atrial fibrillation with heart failure.
Eur J Heart Fail. 2021 Nov 23. doi: 10.1002/ejhf.2389.
PubMed

ALNUWAYSIR RIS, Grote Beverborg N, Hoes MF, Markousis-Mavrogenis G, et al
Additional Burden of Iron Deficiency in Heart Failure Patients beyond the Cardio-Renal-Anaemia Syndrome: Findings from the BIOSTAT-CHF Study.
Eur J Heart Fail. 2021 Nov 23. doi: 10.1002/ejhf.2393.
PubMed Abstract available

CULIC V
Digoxin and beta-blockers in patients with heart failure.
Eur J Heart Fail. 2021 Nov 23. doi: 10.1002/ejhf.2392.
PubMed

NAITO R, Kasai T
Bereavement of a child as a risk of heart failure.
Eur J Heart Fail. 2021 Nov 23. doi: 10.1002/ejhf.2388.
PubMed

MADIAS JE
Pathophysiology of Takotsubo syndrome: still a puzzle. Letter regarding the article 'Pathophysiology of Takotsubo syndrome - a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working
Eur J Heart Fail. 2021 Nov 23. doi: 10.1002/ejhf.2390.
PubMed

MAEDER MT
Selexipag and the Pulmonary Hypertension Continuum.
Eur J Heart Fail. 2021 Nov 23. doi: 10.1002/ejhf.2387.
PubMed

BUTLER J, Anker SD, Siddiqi TJ, Coats AJS, et al
Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
Eur J Heart Fail. 2021 Nov 20. doi: 10.1002/ejhf.2386.
PubMed Abstract available

TER MAATEN JM, Beldhuis IE, van der Meer P, Krikken JA, et al
Natriuresis guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium-based Treatment algoritHm in Acute Heart Failure (PUSH-AHF) trial.
Eur J Heart Fail. 2021 Nov 17. doi: 10.1002/ejhf.2385.
PubMed Abstract available

EMMENS JE, Ter Maaten JM, Matsue Y, Figarska SM, et al
Worsening renal function in acute heart failure in the context of diuretic response.
Eur J Heart Fail. 2021 Nov 17. doi: 10.1002/ejhf.2384.
PubMed Abstract available

GREENE SJ, Butler J, Fonarow GC
In-hospital Initiation of Quadruple Medical Therapy for Heart Failure: Making the Post-Discharge Vulnerable Phase Far Less Vulnerable.
Eur J Heart Fail. 2021 Nov 14. doi: 10.1002/ejhf.2382.
PubMed

BUTT JH, Docherty KF, Jhund PS, De Boer RA, et al
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: Insights from DAPA-HF.
Eur J Heart Fail. 2021 Nov 11. doi: 10.1002/ejhf.2381.
PubMed Abstract available

SEFEROVIC PM, Polovina M, Adlbrecht C, BElohlavek J, et al
Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical treatment in heart failure with reduced ejection fraction.
Eur J Heart Fail. 2021 Nov 9. doi: 10.1002/ejhf.2378.
PubMed Abstract available

FERREIRA JP, Liu J, Claggett BL, Vardeny O, et al
Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCAT.
Eur J Heart Fail. 2021 Nov 9. doi: 10.1002/ejhf.2376.
PubMed Abstract available

SEGAR MW, Khan MS, Patel KV, Vaduganathan M, et al
Incorporation of Natriuretic Peptides with Clinical Risk-scores to Predict Heart Failure Among Individuals with Dysglycemia.
Eur J Heart Fail. 2021 Nov 3. doi: 10.1002/ejhf.2375.
PubMed Abstract available

COHEN-SOLAL A, Beauvais F
New treatments for heart failure and exercise capacity.
Eur J Heart Fail. 2021 Nov 1. doi: 10.1002/ejhf.2374.
PubMed

GHANTOUS E, Topilsky Y
Recovery of cardiac function following COVID-19.
Eur J Heart Fail. 2021;23:1913-1915.
PubMed

LASSEN MCH, Skaarup KG, Lind JN, Alhakak AS, et al
Recovery of cardiac function following COVID-19 - ECHOVID-19: a prospective longitudinal cohort study.
Eur J Heart Fail. 2021;23:1903-1912.
PubMed Abstract available

LAMBADIARI V, Mitrakou A, Kountouri A, Thymis J, et al
Association of COVID-19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection.
Eur J Heart Fail. 2021;23:1916-1926.
PubMed Abstract available

DERDA AA, Garg A, Bar C, Thum T, et al
Reply to 'COVID-19 severity, miR-21 targets, and common human genetic variation'.
Eur J Heart Fail. 2021;23:1987-1988.
PubMed

DINGSDAG SA, Clay OK, Quintero GA
COVID-19 severity, miR-21 targets, and common human genetic variation. Letter regarding the article 'Circulating cardiovascular microRNAs in critically ill COVID-19 patients'.
Eur J Heart Fail. 2021;23:1986-1987.
PubMed

TOMASONI D, Adamo M, Metra M
November 2021 at a glance: focus on prevention, comorbidities, cardiogenic shock and novel devices.
Eur J Heart Fail. 2021;23:1803-1805.
PubMed

WITTE KK, Goldberg SL, Kaye D, Starling R, et al
Reply to 'Benefits of transvenous mitral annuloplasty in heart failure with lower degrees of functional mitral regurgitation'.
Eur J Heart Fail. 2021;23:1985-1986.
PubMed

SEFEROVIC PM
Reply to "Endomyocardial biopsy in the hands of the electrophysiologist: the 'one-stop shop' for arrhythmic non-ischaemic cardiomyopathy".
Eur J Heart Fail. 2021;23:1984.
PubMed

COTTER G, Davison B, Metra M, Sliwa K, et al
Amended STRONG-HF study design.
Eur J Heart Fail. 2021;23:1981-1982.
PubMed

CHIONCEL O, Metra M
Cardiogenic shock centres for optimal care coordination and improving outcomes in cardiogenic shock.
Eur J Heart Fail. 2021;23:1938-1941.
PubMed

BARAN DA
A deceptively simple problem: the case of cardiogenic shock.
Eur J Heart Fail. 2021;23:1952-1954.
PubMed

WITTE KK, Kaye DM, Lipiecki J, Siminiak T, et al
Treating symptoms and reversing remodelling: clinical and echocardiographic 1-year outcomes with percutaneous mitral annuloplasty for mild to moderate secondary mitral regurgitation.
Eur J Heart Fail. 2021;23:1971-1978.
PubMed Abstract available

SCHRAGE B, Beer BN, Savarese G, Dabboura S, et al
Eligibility for mechanical circulatory support devices based on current and past randomised cardiogenic shock trials.
Eur J Heart Fail. 2021;23:1942-1951.
PubMed Abstract available

LU DY, Adelsheimer A, Chan K, Yeo I, et al
Impact of hospital transfer to hubs on outcomes of cardiogenic shock in the real world.
Eur J Heart Fail. 2021;23:1927-1937.
PubMed Abstract available

October 2021

FRASER AG, Szymanski P
Heart valve disease, left ventricular hypertrophy, and heart failure: a lifelong relationship and continuing clinical responsibility.
Eur J Heart Fail. 2021 Oct 24. doi: 10.1002/ejhf.2373.
PubMed

WEI D, Li J, Janszky I, Chen H, et al
Death of a child and the risk of heart failure: a population-based cohort study from Denmark and Sweden.
Eur J Heart Fail. 2021 Oct 24. doi: 10.1002/ejhf.2372.
PubMed Abstract available

OMEROVIC E, Citro R, Bossone E, Redfors B, et al
Pathophysiology of Takotsubo Syndrome - a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of Cardiology - Part 2: vascular pathophysiology, gend
Eur J Heart Fail. 2021 Oct 16. doi: 10.1002/ejhf.2368.
PubMed Abstract available

MINANA G, Bayes-Genis A, Nunez J
Iron deficiency testing and treatment in heart failure: the eyes are useless when the mind is blind.
Eur J Heart Fail. 2021 Oct 16. doi: 10.1002/ejhf.2365.
PubMed

MARTENS P
Detecting Subclinical Congestion in Stage A/B pre-Heart Failure - A glimpse into the future?
Eur J Heart Fail. 2021 Oct 16. doi: 10.1002/ejhf.2366.
PubMed

TROMP J, Packer M, Lam C
The diverging role of epicardial adipose tissue in heart failure with reduced and preserved ejection fraction: not all fat is created equal.
Eur J Heart Fail. 2021 Oct 16. doi: 10.1002/ejhf.2363.
PubMed

ADAMO M, Metra M
Can mild to moderate secondary mitral regurgitation be a therapeutic target for symptomatic patients with heart failure with reduced ejection fraction?
Eur J Heart Fail. 2021 Oct 16. doi: 10.1002/ejhf.2362.
PubMed

CUTHBERT JJ, Pellicori P, Flockton R, Kallvikbacka-Bennett A, et al
The prevalence and clinical associations of ultrasound measures of congestion in patients at risk of developing heart failure.
Eur J Heart Fail. 2021 Oct 10. doi: 10.1002/ejhf.2353.
PubMed Abstract available

LAUDER L, Pereira TV, Degenhardt MC, Ewen S, et al
Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: A systematic review and meta-analysis.
Eur J Heart Fail. 2021 Oct 10. doi: 10.1002/ejhf.2360.
PubMed Abstract available

LOGEART D, Berthelot E, Bihry N, Eschalier R, et al
Early and short-term intensive management after discharge for patients hospitalized with acute heart failure, a randomized study (ECAD-HF).
Eur J Heart Fail. 2021 Oct 9. doi: 10.1002/ejhf.2357.
PubMed Abstract available

KRZESINSKI P, Jankowska EA, Siebert J, Galas A, et al
Effects of an outpatient intervention comprising nurse-led non-invasive assessments, telemedicine support and remote cardiologists' decisions in patients with heart failure (AMULET Study): a randomised controlled trial.
Eur J Heart Fail. 2021 Oct 6. doi: 10.1002/ejhf.2358.
PubMed Abstract available

ROSANO G, Jankowska EA, Ray R, Metra M, et al
COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology.
Eur J Heart Fail. 2021 Oct 6. doi: 10.1002/ejhf.2356.
PubMed Abstract available

Corrigendum to 'Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials' [Eur J Heart Fail 2016;18:684-692].
Eur J Heart Fail. 2021 Oct 4. doi: 10.1002/ejhf.2354.
PubMed

TOMASONI D, Adamo M, Metra M
October 2021 at a glance: focus on imaging, biomarkers and comorbidities.
Eur J Heart Fail. 2021;23:1569-1571.
PubMed

PACKER M, Zannad F, Butler J, Filippatos G, et al
Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial.
Eur J Heart Fail. 2021;23:1798-1799.
PubMed

BEN GAL T, Ben Avraham B, Milicic D, Crespo-Leiro MG, et al
Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary.
Eur J Heart Fail. 2021;23:1597-1609.
PubMed Abstract available

GUAZZI M, Adamo M
Cardiac output in severe tricuspid regurgitation: when more is less.
Eur J Heart Fail. 2021;23:1795-1797.
PubMed

CAMPOCHIARO C, De Luca G, Dagna L
Cardiac immune-related adverse events: an immune-cardio-oncology puzzle.
Eur J Heart Fail. 2021;23:1748-1749.
PubMed

USMAN MS, Pitt B, Butler J
Target trial emulations: bridging the gap between clinical trial and real-world data.
Eur J Heart Fail. 2021;23:1708-1711.
PubMed

ENRIQUEZ-SARANO M, Benfari G, Messika-Zeitoun D, Grigioni F, et al
Functional mitral regurgitation: a proportionate or disproportionate focus of attention?
Eur J Heart Fail. 2021;23:1759-1762.
PubMed

PATTERSON T, Gregson J, Erglis A, Joseph J, et al
Two-year outcomes from the MitrAl ValvE RepaIr Clinical (MAVERIC) trial: a novel percutaneous treatment of functional mitral regurgitation.
Eur J Heart Fail. 2021;23:1775-1783.
PubMed Abstract available

CAIFFA T, De Luca A, Biagini E, Lupi L, et al
Impact on clinical outcomes of right ventricular response to percutaneous correction of secondary mitral regurgitation.
Eur J Heart Fail. 2021;23:1765-1774.
PubMed Abstract available

UNTERHUBER M, Kresoja KP, Besler C, Rommel KP, et al
Cardiac output states in patients with severe functional tricuspid regurgitation: impact on treatment success and prognosis.
Eur J Heart Fail. 2021;23:1784-1794.
PubMed Abstract available

RIZZO S, De Gaspari M, Basso C
Immune checkpoint inhibitor myocarditis: a call for standardized histopathologic criteria.
Eur J Heart Fail. 2021;23:1736-1738.
PubMed

ZENG DX, Jiang JH
Letter regarding the article 'Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure'.
Eur J Heart Fail. 2021;23:1800.
PubMed

TREVISAN M, Fu EL, Xu Y, Savarese G, et al
Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care.
Eur J Heart Fail. 2021;23:1698-1707.
PubMed Abstract available

RUBIO-INFANTE N, Ramirez-Flores YA, Castillo EC, Lozano O, et al
Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis.
Eur J Heart Fail. 2021;23:1739-1747.
PubMed Abstract available

PALASKAS NL, Segura A, Lelenwa L, Siddiqui BA, et al
Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy.
Eur J Heart Fail. 2021;23:1725-1735.
PubMed Abstract available

September 2021

HALLE M, Schobel C, Winzer EB, Bernhardt P, et al
A randomized clinical trial on the short-term effects of 12 weeks sacubitril/valsartan versus enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: Results from the ACTIVITY-HF study.
Eur J Heart Fail. 2021 Sep 30. doi: 10.1002/ejhf.2355.
PubMed Abstract available

CODINA P, Lupon J, Borrellas A, Spitaleri G, et al
Head-to-head comparison of contemporary heart failure risk scores.
Eur J Heart Fail. 2021 Sep 24. doi: 10.1002/ejhf.2352.
PubMed Abstract available

YEOH SE, Dewan P, Serenelli M, Ferreira JP, et al
Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES.
Eur J Heart Fail. 2021 Sep 18. doi: 10.1002/ejhf.2350.
PubMed Abstract available

Corrigendum to 'Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction' [Eur J Heart Fail 2021; 23, 983-991.].
Eur J Heart Fail. 2021 Sep 12. doi: 10.1002/ejhf.2341.
PubMed

KAMMERLANDER AA, Nitsche C, Dona C, Koschutnik M, et al
Heart Failure with Preserved Ejection Fraction after Left-sided Valve Surgery: Prevalent and Relevant.
Eur J Heart Fail. 2021 Sep 10. doi: 10.1002/ejhf.2345.
PubMed Abstract available

COMPAGNUCCI P, Dello Russo A, Casella M
Endomyocardial biopsy in the hands of the electrophysiologist: the 'one-stop shop' for arrhythmic non-ischaemic cardiomyopathy. Letter regarding the article 'Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Fai
Eur J Heart Fail. 2021 Sep 10. doi: 10.1002/ejhf.2340.
PubMed

MEIJERS WC, Bayes-Genis A, Mebazaa A, Bauersachs J, et al
Circulating Heart Failure Biomarkers beyond Natriuretic Peptides: updated review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC).
Eur J Heart Fail. 2021 Sep 8. doi: 10.1002/ejhf.2346.
PubMed Abstract available

INCIARDI RM, Solomon SD
Cardiac Mechanics Assessment and the Risk of Heart Failure in the General Population.
Eur J Heart Fail. 2021 Sep 8. doi: 10.1002/ejhf.2342.
PubMed

HEUSSER K, Wittkoepper J, Bara C, Haverich A, et al
Sympathetic vasoconstrictor activity before and after left ventricular assist device implantation in patients with end-stage heart failure.
Eur J Heart Fail. 2021 Sep 8. doi: 10.1002/ejhf.2344.
PubMed Abstract available

BARTKO PE, Kreidel F, von Bardeleben RS, Goliasch G, et al
Mitral regurgitation tips the scales in acute or worsening heart failure.
Eur J Heart Fail. 2021 Sep 8. doi: 10.1002/ejhf.2343.
PubMed

MOURA B, Aimo A, Al-Mohammad A, Flammer A, et al
Integration of imaging and circulating biomarkers in heart failure: a Consensus Document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the ESC.
Eur J Heart Fail. 2021 Sep 5. doi: 10.1002/ejhf.2339.
PubMed Abstract available

BECHER PM, Schrage B, Benson L, Fudim M, et al
Phenotyping Heart Failure Patients for Iron Deficiency and Use of Intravenous Iron Therapy: Data from the Swedish Heart Failure Registry.
Eur J Heart Fail. 2021 Sep 3. doi: 10.1002/ejhf.2338.
PubMed Abstract available

Abstracts of the Heart Failure 2021 and the World Congress on Acute Heart Failure, 29 June - 1 July 2021, Online Congress.
Eur J Heart Fail. 2021;23 Suppl 2:2-322.
PubMed

CRESPO-LEIRO MG, Barge-Caballero E, Gustafsson F
Efficacy of the COVID-19 vaccine in heart transplant recipients: what we know and what we ignore.
Eur J Heart Fail. 2021;23:1560-1562.
PubMed

ITZHAKI BEN ZADOK O, Shaul AA, Ben-Avraham B, Yaari V, et al
Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients - a prospective cohort study.
Eur J Heart Fail. 2021;23:1555-1559.
PubMed Abstract available

TOMASONI D, Adamo M, Metra M
September 2021 at a glance: focus on biomarkers, sex differences and adherence to medical treatment.
Eur J Heart Fail. 2021;23:1419-1421.
PubMed

BLUMER V, Gayowsky A, Xie F, Greene SJ, et al
Effect of patient-centered transitional care services on patient-reported outcomes in heart failure: sex-specific analysis of the PACT-HF randomized controlled trial.
Eur J Heart Fail. 2021;23:1488-1498.
PubMed Abstract available

TOPS LF, Coats AJS, Ben Gal T
The ever-changing field of mechanical circulatory support: new challenges at the advent of the 'single device era'.
Eur J Heart Fail. 2021;23:1428-1431.
PubMed

AIMO A, Saccaro LF, Borrelli C, Fabiani I, et al
The ergoreflex: how the skeletal muscle modulates ventilation and cardiovascular function in health and disease.
Eur J Heart Fail. 2021;23:1458-1467.
PubMed Abstract available

YUZEFPOLSKAYA M, Colombo PC
Reply to 'Existing evidence supports clinical trials on interventions preventing ventricular assist device infection in patients colonized with Staphylococcus aureus'.
Eur J Heart Fail. 2021;23:1566-1567.
PubMed

NURJADI D, Ruhparwar A, Zanger P
Existing evidence supports clinical trials on interventions preventing ventricular assist device infection in patients colonized with Staphylococcus aureus. Letter regarding the article 'Association of preoperative infections, nasal Staphylococcus aur
Eur J Heart Fail. 2021;23:1566.
PubMed

FERREIRA JP, Konstam MA, McMurray JJV, Butler J, et al
Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial.
Eur J Heart Fail. 2021;23:1477-1484.
PubMed Abstract available

August 2021

CARBONE S, DaSilva-deAbreu A, Lavie CJ
The SGLT2 Inhibitor Dapagliflozin Improves Prognosis in Systolic Heart Failure Independent of the Obesity Paradox.
Eur J Heart Fail. 2021 Aug 23. doi: 10.1002/ejhf.2336.
PubMed

DANDEL M, Hetzer R
Benefits of Transvenous Mitral Annuloplasty in Heart Failure with Lower Degrees of Functional Mitral Regurgitation. Letter regarding the article ' Treating symptoms and reversing remodeling: clinical and echocardiographic 1-year outcomes with percutan
Eur J Heart Fail. 2021 Aug 23. doi: 10.1002/ejhf.2335.
PubMed

PUGLIESE NR, Paneni F, Mazzola M, De Biase N, et al
Impact of epicardial adipose tissue on cardiovascular hemodynamics, metabolic profile, and prognosis in heart failure.
Eur J Heart Fail. 2021 Aug 23. doi: 10.1002/ejhf.2337.
PubMed Abstract available

RICHARDS AM, Pemberton CJ
Progress in proteomic probing for pathogenic pathways in heart failure with preserved ejection fraction.
Eur J Heart Fail. 2021 Aug 18. doi: 10.1002/ejhf.2332.
PubMed

STEWART COATS A
Figures of the Heart Failure Association: Professor Dr. Wilfried Mullens, Board Member, 2018-2022, Coordinator of Study Group of Cardiorenal Dysfunction and Co-coordinator of Committee on Cardiac Devices.
Eur J Heart Fail. 2021 Aug 9. doi: 10.1002/ejhf.2325.
PubMed

STEWART COATS AJ
Figures of the Heart Failure Association: Loreena Hill (HFA Board Member and Nurse representative 2016-2020, and HFA Secretary 2020-2022).
Eur J Heart Fail. 2021 Aug 6. doi: 10.1002/ejhf.2323.
PubMed

STEWART COATS AJ
The HFA further develops it educational engagement working together on an MSc in Heart Failure with St George's Hospital in London.
Eur J Heart Fail. 2021 Aug 6. doi: 10.1002/ejhf.2324.
PubMed

TOMASONI D, Adamo M, Metra M
August 2021 at a glance: focus on cardiomyopathies, medical treatment and devices.
Eur J Heart Fail. 2021;23:1247-1249.
PubMed

HERRINGTON WG, Savarese G, Haynes R, Marx N, et al
Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors.
Eur J Heart Fail. 2021;23:1260-1275.
PubMed Abstract available

SINAGRA G, Dal Ferro M, Gigli M
The heart of dystrophinopathies.
Eur J Heart Fail. 2021;23:1287-1289.
PubMed

GUSTAFSSON F, Netuka I
Progressive elimination of adverse events: the key to success for left ventricular assist devices.
Eur J Heart Fail. 2021;23:1401-1403.
PubMed

ROSARIO KF, DeVore AD
Can we prevent infections in patients with left ventricular assist devices?
Eur J Heart Fail. 2021;23:1416-1418.
PubMed

RESTREPO-CORDOBA MA, Wahbi K, Florian AR, Jimenez-Jaimez J, et al
Prevalence and clinical outcomes of dystrophin-associated dilated cardiomyopathy without severe skeletal myopathy.
Eur J Heart Fail. 2021;23:1276-1286.
PubMed Abstract available

RAPEZZI C, Pavasini R, Serenelli M
The left atrium in cardiac amyloidosis: a valuable but still underused observation window on the overall disease process.
Eur J Heart Fail. 2021;23:1296-1299.
PubMed

YUZEFPOLSKAYA M, Lumish HS, Javaid A, Cagliostro B, et al
Association of preoperative infections, nasal Staphylococcus aureus colonization and gut microbiota with left ventricular assist device outcomes.
Eur J Heart Fail. 2021;23:1404-1415.
PubMed Abstract available

MEHRA MR, Cleveland JC Jr, Uriel N, Cowger JA, et al
Primary results of long-term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implants.
Eur J Heart Fail. 2021;23:1392-1400.
PubMed Abstract available

IUNG B, Urena M
Transcatheter mitral valve repair for primary and secondary mitral regurgitation: new insights from a nationwide registry.
Eur J Heart Fail. 2021;23:1377-1379.
PubMed

MINAMISAWA M, Inciardi RM, Claggett B, Cuddy SAM, et al
Left atrial structure and function of the amyloidogenic V122I transthyretin variant in elderly African Americans.
Eur J Heart Fail. 2021;23:1290-1295.
PubMed Abstract available

COLOMBO A, Mangieri A
Can we set a threshold for the learning curve of MitraClip procedures?
Eur J Heart Fail. 2021;23:1390-1391.
PubMed

CHATTERJEE NA, Levy WC
Looking forward and backward for sudden death risk: competing risk is everywhere.
Eur J Heart Fail. 2021;23:1357-1360.
PubMed

KELLER K, Hobohm L, Schmidtmann I, Munzel T, et al
Centre procedural volume and adverse in-hospital outcomes in patients undergoing percutaneous transvenous edge-to-edge mitral valve repair using MitraClip(R) in Germany.
Eur J Heart Fail. 2021;23:1380-1389.
PubMed Abstract available

BEDOGNI F, Popolo Rubbio A, Grasso C, Adamo M, et al
Italian Society of Interventional Cardiology (GIse) registry Of Transcatheter treatment of mitral valve regurgitaTiOn (GIOTTO): impact of valve disease aetiology and residual mitral regurgitation after MitraClip implantation.
Eur J Heart Fail. 2021;23:1364-1376.
PubMed Abstract available

GILL H, Chehab O, Allen C, Patterson T, et al
The advantages, pitfalls and limitations of guideline-directed medical therapy in patients with valvular heart disease.
Eur J Heart Fail. 2021;23:1325-1333.
PubMed Abstract available

July 2021

SKAARUP KG, Lassen MCH, Johansen ND, Sengelov M, et al
Layer-Specific Global Longitudinal Strain and the Risk of Heart Failure and Cardiovascular Mortality in the General Population: The Copenhagen City Heart Study.
Eur J Heart Fail. 2021 Jul 29. doi: 10.1002/ejhf.2315.
PubMed Abstract available

PANDEY A, Butler J
Improving Exercise Tolerance & Quality of Life in Heart Failure with Preserved Ejection Fraction Time to Think Outside the Heart.
Eur J Heart Fail. 2021 Jul 22. doi: 10.1002/ejhf.2313.
PubMed

KHAN MS, Butler J, Greene SJ
Simultaneous or Rapid Sequence Initiation of Medical Therapies for Heart Failure: Seeking to Avoid the Case of "Too Little, Too Late".
Eur J Heart Fail. 2021 Jul 19. doi: 10.1002/ejhf.2311.
PubMed

SWEDBERG K
The clinical practise of treating patients with chronic heart failure needs to be improved.
Eur J Heart Fail. 2021 Jul 17. doi: 10.1002/ejhf.2309.
PubMed

ADAMSON C, Jhund PS, Docherty KF, Belohlavek J, et al
Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index.
Eur J Heart Fail. 2021 Jul 16. doi: 10.1002/ejhf.2308.
PubMed Abstract available

MILLER RJ, Howlett JG
Untying the Gordian Knot of Sex and Heart Failure Therapy.
Eur J Heart Fail. 2021 Jul 15. doi: 10.1002/ejhf.2299.
PubMed

SAVARESE G, Merlo M, Coats AJ, Metra M, et al
Best of European Journal of Heart Failure at the ESC/HFA Heart Failure Congress 2021.
Eur J Heart Fail. 2021 Jul 15. doi: 10.1002/ejhf.2306.
PubMed

ANKER MS, Tschope C
Reply to 'Heart failure with preserved ejection fraction and COVID-19: which comes first, the chicken or the egg?'
Eur J Heart Fail. 2021 Jul 15. doi: 10.1002/ejhf.2305.
PubMed

GRAHAM FJ, Pellicori P, Cleland JGF, Clark AL, et al
REPLY to a letter regarding the article "Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure".
Eur J Heart Fail. 2021 Jul 14. doi: 10.1002/ejhf.2304.
PubMed

GREENE SJ, Butler J, Metra M
Another Reason to Embrace Quadruple Medical Therapy for Heart Failure: Medications Enabling Tolerance of the Others.
Eur J Heart Fail. 2021 Jul 14. doi: 10.1002/ejhf.2301.
PubMed

NUNEZ J, de la Espriella R, Minana G, Santas E, et al
Antigen Carbohydrate 125 as a Biomarker in Heart Failure: a Narrative Review.
Eur J Heart Fail. 2021 Jul 9. doi: 10.1002/ejhf.2295.
PubMed Abstract available

KRESOJA KP, Rommel KP, Wachter R, Henger S, et al
Proteomics to Improve Phenotyping in Obese Patients with Heart Failure with Preserved Ejection Fraction.
Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2291.
PubMed Abstract available

BAYES-GENIS A, Januzzi JL, Richards AM, Arfsten H, et al
The "Peptide for Life" Initiative: A Call for Action to Provide Equal Access for the Use of Natriuretic Peptides in the Diagnosis of Acute Heart Failure across Europe.
Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2293.
PubMed

BISSON A, Ding WY, Bodin A, Lip GYH, et al
Clinical outcomes with digoxin vs beta-blocker for heart rate control in permanent atrial fibrillation with heart failure.
Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2292.
PubMed

CARAVITA S, Iacovoni A, Senni M
The right side of the circulation in not secondary heart failure with preserved ejection fraction: an elephant in the room?
Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2294.
PubMed

TOMASONI D, Adamo M, Metra M
July 2021 at a glance: focus on blood volume distribution, haemodynamics and adherence to therapy.
Eur J Heart Fail. 2021;23:1059-1061.
PubMed

MEHRA MR, Crandall DL, Gustafsson F, Jorde UP, et al
Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial.
Eur J Heart Fail. 2021;23:1226-1237.
PubMed Abstract available

TURNER JM, Cox ZL, Testani JM
Improving renal function during diuresis: useful information or just noise?
Eur J Heart Fail. 2021;23:1131-1133.
PubMed

AMMIRATI E, Varrenti M, Veronese G, Fanti D, et al
Prevalence and outcome of patients with acute myocarditis and positive viral search on nasopharyngeal swab.
Eur J Heart Fail. 2021;23:1242-1245.
PubMed

PELLICORI P, Fitchett D, Kosiborod MN, Ofstad AP, et al
Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial.
Eur J Heart Fail. 2021;23:1085-1093.
PubMed Abstract available

KUSCHYK J, Falk P, Demming T, Marx O, et al
Long-term clinical experience with cardiac contractility modulation therapy delivered by the Optimizer Smart system.
Eur J Heart Fail. 2021;23:1160-1169.
PubMed Abstract available

DENIAU B, Picod A, Azibani F, Gayat E, et al
The CLIP-based mortality score in cardiogenic shock: suitable only for cardiogenic shock?
Eur J Heart Fail. 2021;23:1240-1242.
PubMed

ZYMLINSKI R, Biegus J, Ponikowski P
Not all fluid overloads are the same: some practical considerations for better decongestion.
Eur J Heart Fail. 2021;23:1106-1109.
PubMed

KARAMICHALAKIS N, Ikonomidis I, Parissis J, Simitsis P, et al
Association of ventricular-arterial interaction with the response to cardiac resynchronization therapy.
Eur J Heart Fail. 2021;23:1238-1240.
PubMed

FINOCCHIARO G, Sinagra G, Papadakis M, Carr-White G, et al
The labyrinth of nomenclature in Cardiology. Eternal dilemmas and new challenges on the horizon in the personalized medicine era.
Eur J Heart Fail. 2021;23:1062-1067.
PubMed

June 2021

PONIKOWSKI P, Alemayehu W, Oto A, Bahit MC, et al
Vericiguat in Patients with Atrial Fibrillation and Heart Failure with Reduced Ejection Fraction: Insights from the VICTORIA trial.
Eur J Heart Fail. 2021 Jun 30. doi: 10.1002/ejhf.2285.
PubMed Abstract available

MCEWAN P, Ponikowski P, Davis JA, Rosano G, et al
Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising AFFIRM-AHF.
Eur J Heart Fail. 2021 Jun 30. doi: 10.1002/ejhf.2270.
PubMed Abstract available

YAFASOVA A, Butt JH, Rorth R
Troponin - An important prognostic biomarker in patients with heart failure and reduced ejection fraction?
Eur J Heart Fail. 2021 Jun 29. doi: 10.1002/ejhf.2282.
PubMed

GREENE SJ, Fonarow GC
Clinical Inertia and Medical Therapy for Heart Failure: The Unintended Harms of "First, Do No Harm".
Eur J Heart Fail. 2021 Jun 29. doi: 10.1002/ejhf.2283.
PubMed

ABDIN A, Bohm M
Renal function and vericiguat in heart failure patients: Light at the end of the tunnel!
Eur J Heart Fail. 2021 Jun 26. doi: 10.1002/ejhf.2280.
PubMed

KHAN MS, Khan F, Fonarow GC, Sreenivasan J, et al
Dietary Interventions and Nutritional Supplements for Heart Failure: A Systematic Appraisal and Evidence Map.
Eur J Heart Fail. 2021 Jun 26. doi: 10.1002/ejhf.2278.
PubMed Abstract available

ANKER SD, Khan MS, Shahid I, Filippatos G, et al
SGLT-2 Inhibitors in Heart Failure with Preserved Ejection Fraction Reasons for Optimism.
Eur J Heart Fail. 2021 Jun 26. doi: 10.1002/ejhf.2279.
PubMed

SHAH SJ, Cowie MR, Wachter R, Szecsody P, et al
Baseline Characteristics of Patients in the PARALLAX Trial: Insights into Quality of Life and Exercise Capacity in Heart Failure with Preserved Ejection Fraction.
Eur J Heart Fail. 2021 Jun 25. doi: 10.1002/ejhf.2277.
PubMed Abstract available

PAGNESI M, Adamo M, Sama IE, Anker SD, et al
Impact of mitral regurgitation in patients with worsening heart failure: Insights from BIOSTAT-CHF.
Eur J Heart Fail. 2021 Jun 23. doi: 10.1002/ejhf.2276.
PubMed Abstract available

BARATTO C, Caravita S, Parati G
HFpEF and COVID-19: which comes first, the chicken or the egg? Letter regarding the article "Heart Failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings".
Eur J Heart Fail. 2021 Jun 17. doi: 10.1002/ejhf.2273.
PubMed

SAVARESE G, Bodegard J, Norhammar A, Sartipy P, et al
Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden).
Eur J Heart Fail. 2021 Jun 15. doi: 10.1002/ejhf.2271.
PubMed Abstract available

RICHARDS AM, Pemberton CJ
Urinary Peptides in Heart Failure - the need for care with pees and cues.
Eur J Heart Fail. 2021 Jun 12. doi: 10.1002/ejhf.2269.
PubMed

PATEL RB, Shah SJ
The Splanchnic Reservoir: An Oasis for Blood Volume in Heart Failure with Preserved Ejection Fraction?
Eur J Heart Fail. 2021 Jun 12. doi: 10.1002/ejhf.2268.
PubMed

STOLFO D, Savarese G
Association Between Heart Failure and Cancer: Is Gender the Answer?
Eur J Heart Fail. 2021 Jun 11. doi: 10.1002/ejhf.2261.
PubMed

BHATT AS, Vaduganathan M, Claggett BL, Liu J, et al
Effect of Sacubitril/Valsartan versus Enalapril on Changes in Heart Failure Therapies Over Time: The PARADIGM-HF Trial.
Eur J Heart Fail. 2021 Jun 7. doi: 10.1002/ejhf.2259.
PubMed Abstract available

TOMASONI D, Adamo M, Metra M
June 2021 at a glance: focus on epidemiology, biomarkers and medical treatment.
Eur J Heart Fail. 2021;23:847-849.
PubMed

SEGAR MW, Pandey A
Omics, machine learning, and personalized medicine in heart failure with preserved ejection fraction: promising future or false hope?
Eur J Heart Fail. 2021;23:992-994.
PubMed

FERREIRA JP
Circulating levels of procollagen type I carboxy-terminal propeptide reflect myocardial fibrosis.
Eur J Heart Fail. 2021;23:945-946.
PubMed

RAAFS AG, Verdonschot JAJ, Henkens MTHM, Adriaans BP, et al
The combination of carboxy-terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy - A multilevel assessment o
Eur J Heart Fail. 2021;23:933-944.
PubMed Abstract available

GARCIA-PAVIA P, Bengel F, Brito D, Damy T, et al
Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy.
Eur J Heart Fail. 2021;23:895-905.
PubMed Abstract available

HAVERKAMP W, Butler J, Anker SD
Can we trust a smartwatch ECG? Potential and limitations.
Eur J Heart Fail. 2021;23:850-853.
PubMed

SATTAR N, Januzzi JL
Can biomarkers help find the 'sweet spot' for treating patients with diabetes?
Eur J Heart Fail. 2021;23:1037-1039.
PubMed

PARCHA V, Arora P
Sodium-glucose co-transporter 2 inhibitors: strength of evidence for a cardio-renal-metabolic therapy.
Eur J Heart Fail. 2021;23:1009-1011.
PubMed

GREENBERG B, Adler E, Campagnari C, Yagil A, et al
A machine learning risk score predicts mortality across the spectrum of left ventricular ejection fraction.
Eur J Heart Fail. 2021;23:995-999.
PubMed Abstract available

DAMY T, Sultan MB, Witteles R
Reply to the letter regarding the article 'Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study'.
Eur J Heart Fail. 2021;23:1057-1058.
PubMed

May 2021

PACKER M, Januzzi JL Jr, Ferreira JP, Anker SD, et al
Concentration-Dependent Clinical and Prognostic Importance of High-Sensitivity Cardiac Troponin T in Heart Failure and a Reduced Ejection Fraction and the Influence of Empagliflozin: the EMPEROR-Reduced Trial.
Eur J Heart Fail. 2021 May 30. doi: 10.1002/ejhf.2256.
PubMed Abstract available

BUTLER J, Yang M, Sawhney B, Chakladar S, et al
Treatment Patterns and Clinical Outcomes Among Patients <65 Years with a Worsening Heart Failure Event.
Eur J Heart Fail. 2021 May 30. doi: 10.1002/ejhf.2252.
PubMed Abstract available

SORIMACHI H, Burkhoff D, Verbrugge FH, Omote K, et al
Obesity, Venous Capacitance, and Venous Compliance in Heart Failure with Preserved Ejection Fraction.
Eur J Heart Fail. 2021 May 30. doi: 10.1002/ejhf.2254.
PubMed Abstract available

SOLOMON SD, de Boer RA, DeMets D, Hernandez AF, et al
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.
Eur J Heart Fail. 2021 May 29. doi: 10.1002/ejhf.2249.
PubMed Abstract available

TKACZYSZYN M, Comin-Colet J, Voors AA, van Veldhuisen DJ, et al
Iron deficiency contributes to the resistance to endogenous erythropoietin in anaemic heart failure patients.
Eur J Heart Fail. 2021 May 29. doi: 10.1002/ejhf.2253.
PubMed Abstract available

GRAHAM FJ, Masini G, Pellicori P, Cleland JGF, et al
Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure.
Eur J Heart Fail. 2021 May 28. doi: 10.1002/ejhf.2251.
PubMed Abstract available

FADINI GP, Avogaro A
A simple way to spotlight hidden heart failure in type 2 diabetes?
Eur J Heart Fail. 2021 May 28. doi: 10.1002/ejhf.2258.
PubMed

VAN SPALL HG, Averbuch T, Damman K, Voors AA, et al
Risk and Risk Reduction In Trials of Heart Failure with Reduced Ejection Fraction: Absolute or Relative?
Eur J Heart Fail. 2021 May 26. doi: 10.1002/ejhf.2248.
PubMed

SEFEROVIC PM, Tsutsui H, McNamara DM, Ristic AD, et al
Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy.
Eur J Heart Fail. 2021 May 19. doi: 10.1002/ejhf.2190.
PubMed Abstract available

VOORS AA, Mulder H, Reyes E, Cowie MR, et al
Renal Function and the Effects of Vericiguat in Patients with Worsening Heart Failure with Reduced Ejection Fraction: Insights from VICTORIA (VerICiguaT Global Study in Subjects with HFrEF) Trial.
Eur J Heart Fail. 2021 May 17. doi: 10.1002/ejhf.2221.
PubMed Abstract available

BRAUNWALD E
The War on Heart Failure.
Eur J Heart Fail. 2021 May 16. doi: 10.1002/ejhf.2217.
PubMed

KAPELIOS CJ, Canepa M, Savarese G, Lund LH, et al
Use of loop diuretics in chronic heart failure: do we adhere to the Hippocratian principle "do no harm"?
Eur J Heart Fail. 2021 May 16. doi: 10.1002/ejhf.2218.
PubMed

BISTOLA V, Simitsis P, Parissis J, Ouwerkerk W, et al
Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum.
Eur J Heart Fail. 2021 May 16. doi: 10.1002/ejhf.2219.
PubMed Abstract available

TOCCHETTI CG, Mercurio V, Maack C
The multifaceted mechanisms of nitroxyl in heart failure: Inodilator or "only" vasodilator?
Eur J Heart Fail. 2021 May 2. doi: 10.1002/ejhf.2204.
PubMed

HILL L, Lambrinou E, Antoniou S
Optimizing evidence-based heart failure medication: Every contact counts.
Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2213.
PubMed

ROSANO GMC, Moura B, Metra M, Bauersachs J, et al
Patients profiling in Heart Failure for tailoring medical therapy A consensus document of the Heart Failure Association of the European Society of Cardiology.
Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2206.
PubMed

LEEDY DJ, Reding KW, Vasbinder AL, Anderson GL, et al
The association between heart failure and incident cancer in women: An analysis of the Women's Health Initiative.
Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2207.
PubMed Abstract available

MALEK F, Gajewski P, Zymlinski R, Janczak D, et al
Surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserved ejection fraction: First-in-human clinical trial.
Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2209.
PubMed Abstract available

MULDER BA, van Veldhuisen DJ, Rienstra M
Sudden cardiac death in heart failure: more than meets the eye.
Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2212.
PubMed

HADZIBEGOVIC S, Lena A, Churchill TW, Ho JE, et al
Heart Failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings.
Eur J Heart Fail. 2021 May 1. doi: 10.1002/ejhf.2210.
PubMed Abstract available

TOMASONI D, Adamo M, Metra M
May 2021 at a glance: focus on acute heart failure and heart failure with preserved ejection fraction.
Eur J Heart Fail. 2021;23:691-692.
PubMed

MULLENS W, Martens P, Witte K, Cowie MR, et al
Reply to 'Why mechanical dyssynchrony remains relevant to cardiac resynchronization therapy'.
Eur J Heart Fail. 2021;23:844-845.
PubMed

TOMASONI D, Coats AJS
The Altmetric Attention Score: how science tries to meet social media.
Eur J Heart Fail. 2021;23:693-697.
PubMed

SUGUMAR H, Nanayakkara S, Vizi D, Wright L, et al
A prospective STudy using invAsive haemodynamic measurements foLLowing catheter ablation for AF and early HFpEF: STALL AF-HFpEF.
Eur J Heart Fail. 2021;23:785-796.
PubMed Abstract available

KHEDRAKI R, Tang WHW
Identifying sodium non-excretors: heart failure's emerging golden ticket for risk stratification.
Eur J Heart Fail. 2021;23:740-742.
PubMed

VEENIS JF, Brugts JJ, Yalcin YC, Caliskan K, et al
Reply to 'Aortic valve surgery and left ventricular assist device: lights and shadows'.
Eur J Heart Fail. 2021;23:842-843.
PubMed

LOARDI C, Zanobini M
Aortic valve surgery and left ventricular assist device: lights and shadows. Letter regarding the article 'Survival following a concomitant aortic valve procedure during left ventricular assist device surgery: an ISHLT Mechanically Assisted Circulator
Eur J Heart Fail. 2021;23:841-842.
PubMed

BHATT AS, Yanamandala M, Konstam MA
For vaptans, as for life, balance is better.
Eur J Heart Fail. 2021;23:751-753.
PubMed

SANDERS-VAN WIJK S, Barandiaran Aizpurua A, Brunner-La Rocca HP, Henkens MTHM, et al
The HFA-PEFF and H2 FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction.
Eur J Heart Fail. 2021;23:838-840.
PubMed

April 2021

FRASER AG, Tschope C, de Boer RA
Diagnostic recommendations and phenotyping for heart failure with preserved ejection fraction - knowing more and understanding less?
Eur J Heart Fail. 2021 Apr 30. doi: 10.1002/ejhf.2205.
PubMed

BEUSEKAMP JC, Tromp J, Boorsma EM, Heerspink HJL, et al
Effects of SGLT2 inhibition with Empagliflozin on Potassium Handling in Patients with Acute Heart Failure.
Eur J Heart Fail. 2021 Apr 26. doi: 10.1002/ejhf.2197.
PubMed

FUDIM M, Ponikowski P, Burkhoff D, Dunlap M, et al
Splanchnic Nerve Modulation in Heart Failure: Mechanistic Overview, Initial Clinical Experience, and Safety Considerations.
Eur J Heart Fail. 2021 Apr 22. doi: 10.1002/ejhf.2196.
PubMed Abstract available

HE T, Mischak M, Clark AL, Campbell RT, et al
Urinary peptides in heart failure: a link to molecular pathophysiology.
Eur J Heart Fail. 2021 Apr 21. doi: 10.1002/ejhf.2195.
PubMed Abstract available

FINE NM, Howlett JG
Cautious optimism for machine learning techniques for prediction of heart failure outcomes.
Eur J Heart Fail. 2021 Apr 20. doi: 10.1002/ejhf.2192.
PubMed

NASSIF M, Butler J
Moving in the Right Direction but Not There Yet. The Utility, Measurement, and Analysis of Health Status in Heart Failure Trials.
Eur J Heart Fail. 2021 Apr 20. doi: 10.1002/ejhf.2193.
PubMed

JERING KS, Claggett B, Pfeffer MA, Granger C, et al
Prospective ARNI versus ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): Design and Baseline Characteristics.
Eur J Heart Fail. 2021 Apr 12. doi: 10.1002/ejhf.2191.
PubMed Abstract available

BAYES-GENIS A, Lupon J
Heart failure is ejection fraction in motion.
Eur J Heart Fail. 2021 Apr 9. doi: 10.1002/ejhf.2185.
PubMed

ABRAHAM WT
Interatrial Shunting for the Treatment of Heart Failure: An On-Demand, Self-Regulating Left Atrial Pressure Lowering System.
Eur J Heart Fail. 2021 Apr 8. doi: 10.1002/ejhf.2184.
PubMed

SORENSEN TB, Minamisawa M, Liu J, Claggett B, et al
The Effect of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Right Ventricular Structure and Function in Chronic Systolic Heart Failure (COSMIC -HF).
Eur J Heart Fail. 2021 Apr 7. doi: 10.1002/ejhf.2181.
PubMed

FERREIRA JP
Cognitive function assessment for personalized heart failure disease management programmes.
Eur J Heart Fail. 2021 Apr 7. doi: 10.1002/ejhf.2183.
PubMed

GIRERD N, Felker GM
The lower is not always the better: a better understanding of loop diuretics in heart failure.
Eur J Heart Fail. 2021 Apr 7. doi: 10.1002/ejhf.2182.
PubMed

BOLLI R, Mitrani RD, Hare JM, Pepine CJ, et al
A Phase II Study of Autologous Mesenchymal Stromal Cells and c-kit Positive Cardiac Cells, Alone or in Combination, in Patients with Ischemic Heart Failure: The CCTRN CONCERT-HF Trial.
Eur J Heart Fail. 2021 Apr 3. doi: 10.1002/ejhf.2178.
PubMed Abstract available

PAGNESI M, Adamo M, Metra M
April 2021 at a glance: focus on systolic function, quality of life and treatment in heart failure.
Eur J Heart Fail. 2021;23:505-506.
PubMed

BAYES-GENIS A
The CONCERT-HF trial: a sweet and sour symphony.
Eur J Heart Fail. 2021;23:675-676.
PubMed

GARCIA-PAVIA P, Rapezzi C, Adler Y, Arad M, et al
Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.
Eur J Heart Fail. 2021;23:512-526.
PubMed Abstract available

BOUDOULAS KD, Boudoulas H
Time and left ventricular function: the forgotten dynamic factor.
Eur J Heart Fail. 2021;23:552-554.
PubMed

STRANGE G, Playford D, Scalia GM, Celermajer DS, et al
Change in ejection fraction and long-term mortality in adults referred for echocardiography.
Eur J Heart Fail. 2021;23:555-563.
PubMed Abstract available

COATS AJS, Rosano G
Treatments delayed lead to lives lost.
Eur J Heart Fail. 2021;23:511.
PubMed

DOCHERTY KF, Curtain JP, Anand IS, Bengtsson O, et al
Effect of dapagliflozin on anaemia in DAPA-HF.
Eur J Heart Fail. 2021;23:617-628.
PubMed Abstract available

DOBNER S
Letter regarding the article 'Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study'.
Eur J Heart Fail. 2021;23:681-682.
PubMed

HAGNAS MJ, Grasso C, Di Salvo ME, Sardone A, et al
Effect of post-procedural evidence-based therapy on 2-year prognosis after transcatheter mitral valve repair.
Eur J Heart Fail. 2021;23:677-679.
PubMed

March 2021

WETTERSTEN N, Horiuchi Y, van Veldhuisen DJ, Ix JH, et al
Decongestion Discriminates Risk for One Year Mortality in Patients with Improving Renal Function in Acute Heart Failure.
Eur J Heart Fail. 2021 Mar 31. doi: 10.1002/ejhf.2179.
PubMed Abstract available

HUYNH QL, Whitmore K, Negishi K, DePasquale CG, et al
Cognitive Impairment as a Determinant of Response to Management Plans After Heart Failure Admission.
Eur J Heart Fail. 2021 Mar 31. doi: 10.1002/ejhf.2177.
PubMed Abstract available

BARAKAT MF, Amin-Youseff G, Okonko DO
Oral Sucrosomial Iron in Heart Failure with a Reduced Ejection Fraction.
Eur J Heart Fail. 2021 Mar 31. doi: 10.1002/ejhf.2176.
PubMed

UIJL A, Savarese G, Vaartjes I, Dahlstrom U, et al
Identification of Distinct Phenotypic Clusters in Heart Failure with Preserved Ejection Fraction.
Eur J Heart Fail. 2021 Mar 29. doi: 10.1002/ejhf.2169.
PubMed Abstract available

KALOGEROPOULOS AP, Hotelling J, Skopicki HA
Blood Counts: Targeting Anemia in Patients with Heart Failure.
Eur J Heart Fail. 2021 Mar 29. doi: 10.1002/ejhf.2173.
PubMed

KHAN MS, Fonarow GC, Greene SJ
SGLT-2 Inhibitors for Heart Failure: Clinical Trial Efficacy and Clinical Practice Effectiveness.
Eur J Heart Fail. 2021 Mar 29. doi: 10.1002/ejhf.2170.
PubMed

WAN SH, Pandey A
Targeting the nitrate-nitrite-nitric oxide pathway in heart failure with preserved ejection fraction: too soon to say no to nitric oxide?
Eur J Heart Fail. 2021 Mar 29. doi: 10.1002/ejhf.2171.
PubMed

KHAN MS, Usman MS, Butler J
Etiology Of Heart Failure Is In The Eye Of The Beholder: Does It Even Matter?
Eur J Heart Fail. 2021 Mar 26. doi: 10.1002/ejhf.2166.
PubMed

PACKER M
What Causes Exertional Dyspnea in Patients With Atrial Fibrillation? Implications for Catheter Ablation in Patients With Heart Failure.
Eur J Heart Fail. 2021 Mar 26. doi: 10.1002/ejhf.2164.
PubMed

BHATT AS, Varshney AS, Nekoui M, Moscone A, et al
Virtual Optimization of Guideline-Directed Medical Therapy in Hospitalized Patients with Heart Failure with Reduced Ejection Fraction: the IMPLEMENT-HF Pilot Study.
Eur J Heart Fail. 2021 Mar 26. doi: 10.1002/ejhf.2163.
PubMed Abstract available

METRA M, Coats AJS
Why we love heart failure. An introduction to the universal definition of heart failure.
Eur J Heart Fail. 2021 Mar 26. doi: 10.1002/ejhf.2168.
PubMed

GUPTA P, Voors AA, Patel P, Lane D, et al
Non-adherence to heart failure medications predicts clinical outcomes: Assessment in a single spot urine sample by liquid chromatography - tandem mass spectrometry (results of a prospective multicentre study).
Eur J Heart Fail. 2021 Mar 23. doi: 10.1002/ejhf.2160.
PubMed

CHIONCEL O, Stewart Coats AJ
National Heart Failure Societies Summit 2020.
Eur J Heart Fail. 2021 Mar 21. doi: 10.1002/ejhf.2157.
PubMed

BOORSMA EM, Ter Maaten JM, Damman K, van Veldhuisen DJ, et al
Dipeptidyl peptidase-3, a marker of the antagonist pathway of the renin-angiotensin-aldosterone system in patients with heart failure.
Eur J Heart Fail. 2021 Mar 20. doi: 10.1002/ejhf.2158.
PubMed Abstract available

RAVERA A, Santema BT, Sama IE, Meyer S, et al
Quality of life in men and women with heart failure: association with outcome, and comparison of the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire.
Eur J Heart Fail. 2021 Mar 16. doi: 10.1002/ejhf.2154.
PubMed Abstract available

TROMP J, Bryant JA, Jin X, van Woerden G, et al
Epicardial fat in heart failure with reduced versus preserved ejection fraction.
Eur J Heart Fail. 2021 Mar 16. doi: 10.1002/ejhf.2156.
PubMed

ZIAEIAN B, Fonarow GC
Making heart failure count.
Eur J Heart Fail. 2021 Mar 13. doi: 10.1002/ejhf.2148.
PubMed

PACKER M, McMurray JJV
Rapid Evidence-Based Sequencing of Foundational Drugs for Heart Failure and a Reduced Ejection Fraction.
Eur J Heart Fail. 2021 Mar 11. doi: 10.1002/ejhf.2149.
PubMed Abstract available

PUVREZ A, Duchenne J, Gorcsan J 3rd, Marwick TH, et al
Why mechanical dyssynchrony remains relevant to cardiac resynchronization therapy. Letter regarding the article 'Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care: a joint position s
Eur J Heart Fail. 2021 Mar 11. doi: 10.1002/ejhf.2150.
PubMed

WOLSK E, Kaye DM, Komtebedde J, Shah SJ, et al
Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction.
Eur J Heart Fail. 2021 Mar 8. doi: 10.1002/ejhf.2146.
PubMed Abstract available

WOOLLEY RJ, Ceelen D, Ouwerkerk W, Tromp J, et al
Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction.
Eur J Heart Fail. 2021 Mar 2. doi: 10.1002/ejhf.2144.
PubMed Abstract available

CARAVITA S, Senni M, Parati G
Reply to: 'The hyperdynamic circulatory profile of patients with COVID-19-related acute vascular distress syndrome'.
Eur J Heart Fail. 2021;23:493-494.
PubMed

TOMASONI D, Petrie MC, Adamo M, Metra M, et al
Renin-angiotensin-aldosterone inhibitors and COVID-19: nearing the end of a media-fuelled controversy.
Eur J Heart Fail. 2021;23:486-488.
PubMed

MAHJOUB Y, Rodenstein DO, Jounieaux V
The hyperdynamic circulatory profile of patients with COVID-19-related acute vascular distress syndrome. Letter regarding the article 'Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical vent
Eur J Heart Fail. 2021;23:493.
PubMed

PAGNESI M, Adamo M, Metra M
March 2021 at a glance: focus on epidemiology, prevention and COVID-19.
Eur J Heart Fail. 2021;23:347-349.
PubMed

CARO-CODON J, Rey JR, Buno A, Iniesta AM, et al
Characterization of NT-proBNP in a large cohort of COVID-19 patients.
Eur J Heart Fail. 2021;23:456-464.
PubMed Abstract available

GARG A, Seeliger B, Derda AA, Xiao K, et al
Circulating cardiovascular microRNAs in critically ill COVID-19 patients.
Eur J Heart Fail. 2021;23:468-475.
PubMed Abstract available

SAVARESE G, Benson L, Sundstrom J, Lund LH, et al
Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis.
Eur J Heart Fail. 2021;23:476-485.
PubMed Abstract available

BRAUNWALD E, Antman EM
The path to universality.
Eur J Heart Fail. 2021;23:381-383.
PubMed

OLSEN FJ, Solomon SD, Biering-Sorensen T
Piecing together the puzzle of sex-specific differences in left ventricular ejection fraction.
Eur J Heart Fail. 2021;23:417-419.
PubMed

CHESSA M, Tutarel O
Adults with congenital heart disease - we need more Europe for a better care.
Eur J Heart Fail. 2021;23:454-455.
PubMed

STEWART S, Playford D, Scalia GM, Currie P, et al
Ejection fraction and mortality: a nationwide register-based cohort study of 499 153 women and men.
Eur J Heart Fail. 2021;23:406-416.
PubMed Abstract available

BRIDA M, Simkova I, Jovovic L, Prokselj K, et al
European Society of Cardiology Working Group on Adult Congenital Heart Disease and Study Group for Adult Congenital Heart Care in Central and South Eastern European Countries consensus paper: current status, provision gaps and investment required.
Eur J Heart Fail. 2021;23:445-453.
PubMed Abstract available

SPERRY BW, Tang Y, Jones PG, Spertus JA, et al
Cumulative events in the TOPCAT trial.
Eur J Heart Fail. 2021;23:491-492.
PubMed

ITO M, Matsue Y, Minamino T
Worsening renal function during intensive blood pressure control: another example of not prognostically relevant creatinine rise?
Eur J Heart Fail. 2021;23:393-395.
PubMed

February 2021

DAUW J, Martens P, Tersalvi G, Schouteden J, et al
Diuretic Response and Effects of Diuretic Omission in Ambulatory Heart Failure Patients on Chronic Low Dose Loop Diuretic Therapy.
Eur J Heart Fail. 2021 Feb 28. doi: 10.1002/ejhf.2145.
PubMed Abstract available

PASCUAL-FIGAL DA
Biochemical or clinical heart failure, not so simple.
Eur J Heart Fail. 2021 Feb 26. doi: 10.1002/ejhf.2128.
PubMed

SEFEROVIC PM, Vardas P, Jankowska EA, Maggioni AP, et al
The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019.
Eur J Heart Fail. 2021 Feb 26. doi: 10.1002/ejhf.2143.
PubMed Abstract available

VERBRUGGE FH, Reddy YNV, Sorimachi H, Omote K, et al
Diagnostic Scores Predict Morbidity and Mortality in Patients Hospitalised for Heart Failure with Preserved Ejection Fraction.
Eur J Heart Fail. 2021 Feb 26. doi: 10.1002/ejhf.2142.
PubMed Abstract available

TURGEON RD, Barry AR, Hawkins NM, Ellis UM, et al
Pharmacotherapy for Heart Failure with Reduced Ejection Fraction and Health-Related Quality of Life: Systematic Review and Meta-Analysis.
Eur J Heart Fail. 2021 Feb 25. doi: 10.1002/ejhf.2141.
PubMed Abstract available

LANG NN, Ahmad FA, Cleland JG, O'Connor CM, et al
Hemodynamic Effects of the Nitroxyl Donor Cimlanod (BMS-986231) in Chronic Heart Failure: A Randomized Trial.
Eur J Heart Fail. 2021 Feb 23. doi: 10.1002/ejhf.2138.
PubMed Abstract available

TROMP J, Ponikowski P, Salsali A, Angermann CE, et al
SGLT2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial.
Eur J Heart Fail. 2021 Feb 20. doi: 10.1002/ejhf.2137.
PubMed Abstract available

BHATIA K, Jain V, Gupta K, Bansal A, et al
Prevention of Heart Failure Events with SGLT-2 Inhibitors Across a Spectrum of Cardio-Renal-Metabolic Risk.
Eur J Heart Fail. 2021 Feb 20. doi: 10.1002/ejhf.2135.
PubMed Abstract available

SLIWA K, van der Meer P, Petrie MC, Frogoudaki A, et al
Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripar
Eur J Heart Fail. 2021 Feb 20. doi: 10.1002/ejhf.2133.
PubMed Abstract available

FERREIRA JP, Claggett BL, Liu J, Desai AS, et al
Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial.
Eur J Heart Fail. 2021 Feb 20. doi: 10.1002/ejhf.2134.
PubMed Abstract available

BOZKURT B, Coats A, Tsutsui H
A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure Consensus Conference.
Eur J Heart Fail. 2021 Feb 19. doi: 10.1002/ejhf.2115.
PubMed

CHIONCEL O, Ambrosy AP, Maggioni AP
Temporal Trends in the Outcomes of Acute Heart Failure: Between Consolatory Evidences and Real Progress.
Eur J Heart Fail. 2021 Feb 18. doi: 10.1002/ejhf.2130.
PubMed

BECHER PM, Schrage B, Ferrannini G, Benson L, et al
Use of Sodium-Glucose Co-transporter 2 Inhibitors in Patients with Heart Failure and Type 2 Diabetes Mellitus: Data from the Swedish Heart Failure Registry.
Eur J Heart Fail. 2021 Feb 18. doi: 10.1002/ejhf.2131.
PubMed Abstract available

BUTT JH, Nicolau JC, Verma S, Docherty KF, et al
Efficacy and Safety of Dapagliflozin According to Aetiology in Heart Failure with Reduced Ejection Fraction: Insights from the DAPA-HF trial.
Eur J Heart Fail. 2021 Feb 16. doi: 10.1002/ejhf.2124.
PubMed Abstract available

RICHARDS AM
Cardiac Myosin-Binding Protein C as a candidate biomarker in Heart Failure: rational but not revolutionary.
Eur J Heart Fail. 2021 Feb 15. doi: 10.1002/ejhf.2126.
PubMed

ALHAKAK AS, Teerlink JR, Lindenfeld J, Bohm M, et al
The Significance of Left Ventricular Ejection Time in Heart Failure with Reduced Ejection Fraction.
Eur J Heart Fail. 2021 Feb 15. doi: 10.1002/ejhf.2125.
PubMed Abstract available

MILLER WL, Sorimachi H, Grill DE, Fischer K, et al
Contributions of Cardiac Dysfunction and Volume Status to Central Hemodynamics in Chronic Heart Failure.
Eur J Heart Fail. 2021 Feb 9. doi: 10.1002/ejhf.2121.
PubMed Abstract available

ROHDE LE, Vaduganathan M, Claggett BL, Polanczyk CA, et al
Dynamic Changes in Cardiovascular and Systemic Variables Prior to Sudden Cardiac Death in Heart Failure with Reduced Ejection Fraction: a PARADIGM-HF Analysis.
Eur J Heart Fail. 2021 Feb 9. doi: 10.1002/ejhf.2120.
PubMed Abstract available

VOLTERRANI M, Perrone V, Degli Esposti L
Reply letter regarding the article "Effects of hyperkalemia and non-adherence to renin angiotensin aldosterone system inhibitors (RAASi) in patients affected by heart failure in Italy: a propensity-matched study".
Eur J Heart Fail. 2021 Feb 8. doi: 10.1002/ejhf.2123.
PubMed

PAITAZOGLOU C, Bergmann MW, Ozdemir R, Pfister R, et al
One-year results of the first-in-man study investigating the Atrial-Flow-Regulator for left-atrial shunting in symptomatic heart failure patients: the PRELIEVE study.
Eur J Heart Fail. 2021 Feb 8. doi: 10.1002/ejhf.2119.
PubMed Abstract available

COTTER G, Davison BA, Edwards C, Takagi K, et al
Acute Heart Failure Treatment - A Light at The End of the Tunnel?
Eur J Heart Fail. 2021 Feb 6. doi: 10.1002/ejhf.2116.
PubMed

CLERICO A, Aimo A, Passino C
The pathophysiological and clinical relevance of combined measurement of natriuretic peptides and cardiac troponins for risk prediction of incident heart failure in community-dwelling individuals.
Eur J Heart Fail. 2021 Feb 2. doi: 10.1002/ejhf.2112.
PubMed

Corrigendum to 'Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association of the European Society of Cardiology' [Eur J Heart Fail 2020;22:1315-1341].
Eur J Heart Fail. 2021;23:345.
PubMed

Corrigendum to 'Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncolog
Eur J Heart Fail. 2021;23:345.
PubMed

SMITH N, Tampakakis E
COVID-19 acute respiratory distress syndrome: intriguing haemodynamics of an intriguing syndrome.
Eur J Heart Fail. 2021;23:208-210.
PubMed

PAGNESI M, Adamo M, Metra M
February 2021 at a glance: focus on amyloidosis, myocarditis and cardiomyopathy.
Eur J Heart Fail. 2021;23:201-202.
PubMed

STOGIOS N, Fezza G, Wong JV, Ross HJ, et al
Current challenges for using the Kansas City Cardiomyopathy Questionnaire to obtain a standardized patient-reported health status outcome.
Eur J Heart Fail. 2021;23:205-207.
PubMed

ARNOLD SV, Butler J, Spertus JA
Standardizing the standard: reporting health status in clinical trials.
Eur J Heart Fail. 2021;23:203-204.
PubMed

CASTIGLIONE V, Franzini M, Aimo A, Carecci A, et al
Use of biomarkers to diagnose and manage cardiac amyloidosis.
Eur J Heart Fail. 2021;23:217-230.
PubMed Abstract available

PERLINI S, Mussinelli R, Salinaro F
New effective treatment options reinforce disease awareness: the case of transthyretin cardiac amyloidosis.
Eur J Heart Fail. 2021;23:290-292.
PubMed

LYLE MA, Cooper LT
Failure of intravenous immunoglobulin to improve cardiac function in parvovirus B19-associated chronic dilated cardiomyopathy.
Eur J Heart Fail. 2021;23:310-311.
PubMed

RAPEZZI C, Aimo A, Emdin M
Tafamidis is entering the clinical arena for the treatment of transthyretin-related cardiomyopathy: certainties and unmet needs.
Eur J Heart Fail. 2021;23:286-289.
PubMed

ASLEH R, Amir O, Kushwaha SS
Dynamics of myocardial fibrosis after left ventricular assist device implantation: should speeding up the scar have us scared stiff?
Eur J Heart Fail. 2021;23:335-338.
PubMed

HAZEBROEK MR, Henkens MTHM, Raafs AG, Verdonschot JAJ, et al
Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double-blind, randomized, placebo-controlled clinical trial.
Eur J Heart Fail. 2021;23:302-309.
PubMed Abstract available

BONDERMAN D
How to ATTR-ACT the perfect match?
Eur J Heart Fail. 2021;23:275-276.
PubMed

RAPEZZI C, Giannini F, Campo G
Aortic stenosis, transcatheter aortic valve replacement and transthyretin cardiac amyloidosis: are we progressively unraveling the tangle?
Eur J Heart Fail. 2021;23:259-263.
PubMed

BEZARD M, Kharoubi M, Galat A, Poullot E, et al
Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis.
Eur J Heart Fail. 2021;23:264-274.
PubMed Abstract available

DAMY T, Garcia-Pavia P, Hanna M, Judge DP, et al
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.
Eur J Heart Fail. 2021;23:277-285.
PubMed Abstract available

NICOL M, Deney A, Lairez O, Vergaro G, et al
Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis.
Eur J Heart Fail. 2021;23:231-239.
PubMed Abstract available

ROSENBLUM H, Masri A, Narotsky DL, Goldsmith J, et al
Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis.
Eur J Heart Fail. 2021;23:250-258.
PubMed Abstract available

SINAGRA G, Porcari A, Gentile P, Artico J, et al
Viral presence-guided immunomodulation in lymphocytic myocarditis: an update.
Eur J Heart Fail. 2021;23:211-216.
PubMed Abstract available

January 2021

CANEPA M, Ameri P, Lainscak M
COPD and comorbidities in heart failure: the next frontier of SGLT2 inhibitors?
Eur J Heart Fail. 2021 Jan 27. doi: 10.1002/ejhf.2109.
PubMed

PETRIE MC, Lee MMY, Docherty KF
Sodium-glucose co-transporter 2 inhibitors-the first successful treatment for heart failure with preserved ejection fraction?
Eur J Heart Fail. 2021 Jan 27. doi: 10.1002/ejhf.2108.
PubMed

DOCHERTY KF, Vaduganathan M
OUTSTEP-HF: re-evaluating the role of physical activity measures in drug and device development in heart failure.
Eur J Heart Fail. 2021 Jan 22. doi: 10.1002/ejhf.2106.
PubMed

SUTHAHAR N, Meems LMG, Groothof D, Bakker SJL, et al
Relationship between Body-Mass Index, Cardiovascular Biomarkers and Incident Heart Failure.
Eur J Heart Fail. 2021 Jan 14. doi: 10.1002/ejhf.2102.
PubMed Abstract available

KIMMOUN A, Takagi K, Gall E, Ishihara S, et al
Temporal trends in mortality and readmission after acute heart failure: A systematic review and meta-regression in the past four decades.
Eur J Heart Fail. 2021 Jan 14. doi: 10.1002/ejhf.2103.
PubMed Abstract available

KOZHUHAROV N, Wussler D, Kaier T, Strebel I, et al
Cardiac Myosin-Binding Protein C in the Diagnosis and Risk Stratification of Acute Heart Failure.
Eur J Heart Fail. 2021 Jan 9. doi: 10.1002/ejhf.2094.
PubMed Abstract available

REDDY YNV, Stewart GM, Obokata M, Koepp KE, et al
Peripheral and Pulmonary Effects of Inorganic-Nitrite during Exercise in Heart Failure with Preserved Ejection Fraction.
Eur J Heart Fail. 2021 Jan 9. doi: 10.1002/ejhf.2093.
PubMed Abstract available

KARAVIDAS A, Troganis E, Lazaros G, Balta D, et al
Oral Sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: A non-randomized, open-label, proof-of-concept study.
Eur J Heart Fail. 2021 Jan 9. doi: 10.1002/ejhf.2092.
PubMed Abstract available

TOMASONI D, Adamo M, Metra M
January 2021 at a glance: focus on sex differences, acute heart failure and exercise capacity.
Eur J Heart Fail. 2021;23:1-2.
PubMed

MULLENS W, Martens P
Empagliflozin and renal sodium handling: an intriguing smart osmotic diuretic.
Eur J Heart Fail. 2021;23:79-82.
PubMed

FARMAKIS D, Filippatos G
Arrhythmias in cancer: rhythm is gonna get you!
Eur J Heart Fail. 2021;23:154-156.
PubMed

ANKER MS, von Haehling S, Coats AJS, Riess H, et al
Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study.
Eur J Heart Fail. 2021;23:145-153.
PubMed Abstract available

CHIONCEL O, Collins SP, Seferovic P
Does end-organ dysfunction precede or follow cardiogenic shock in acute decompensated heart failure? The two-faced Janus. Reply.
Eur J Heart Fail. 2021;23:197-198.
PubMed

December 2020

PABEL S, Hamdani N, Sossalla S
A mechanistic rationale for the investigation of SGLT2 inhibitors in HFpEF - Letter regarding the article 'Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved Trial'.
Eur J Heart Fail. 2020 Dec 29. doi: 10.1002/ejhf.2091.
PubMed

DEWAN P, Docherty KF, Bengtsson O, de Boer RA, et al
Effects of dapagliflozin in heart failure with reduced ejection fraction, and COPD: An analysis of DAPA-HF.
Eur J Heart Fail. 2020 Dec 23. doi: 10.1002/ejhf.2083.
PubMed Abstract available

ASLAM MI, Jani V, Lin B, Dunkerly-Eyring B, et al
Pulmonary Artery Pulsatility Index Predicts Right Ventricular Myofilament Dysfunction in Advanced Human Heart Failure.
Eur J Heart Fail. 2020 Dec 21. doi: 10.1002/ejhf.2084.
PubMed

MORIYAMA H, Kohno T, Kohsaka S
Letter regarding the article "Effects of hyperkalemia and non-adherence to renin angiotensin aldosterone system inhibitors (RAASi) in patients affected by heart failure in Italy: a propensity-matched study".
Eur J Heart Fail. 2020 Dec 19. doi: 10.1002/ejhf.2081.
PubMed

DAVISON BA, Senger S, Sama IE, Koch GG, et al
Is Acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF.
Eur J Heart Fail. 2020 Dec 19. doi: 10.1002/ejhf.2077.
PubMed Abstract available

SCHNEIDER B, Ong P
Improving female enrolment in randomized clinical trials of heart failure with reduced ejection fraction to ensure evidence-based health care recommendations.
Eur J Heart Fail. 2020 Dec 19. doi: 10.1002/ejhf.2078.
PubMed

PIEPOLI MF, Hussain RI, Comin-Colet J, Dosantos R, et al
OUTSTEP-HF: Randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction.
Eur J Heart Fail. 2020 Dec 13. doi: 10.1002/ejhf.2076.
PubMed Abstract available

DOCHERTY KF, McMurray JJV
SOLOIST-WHF: Sodium-glucose cotransporter 2 (SGLT2) inhibitors should be initiated in patients hospitalised with worsening heart failure.
Eur J Heart Fail. 2020 Dec 6. doi: 10.1002/ejhf.2075.
PubMed

ZELNIKER TA, Morrow DA, Mosenzon O, Goodrich EL, et al
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without SGLT2 inhibitor therapy in DECLARE-TIMI 58.
Eur J Heart Fail. 2020 Dec 2. doi: 10.1002/ejhf.2073.
PubMed Abstract available

Addendum to the article: 'Improving risk prediction in heart failure using machine learning' [Eur J Heart Fail 2020;22:139-147].
Eur J Heart Fail. 2020;22:2399.
PubMed

WANG N, Cao J, Lal S
COVID-19: getting to the heart of the matter.
Eur J Heart Fail. 2020;22:2216-2218.
PubMed

TOMASONI D, Adamo M, Metra M
December 2020 at a glance: focus on COVID-19, comorbidities and palliative care.
Eur J Heart Fail. 2020;22:2173-2174.
PubMed

LEBEK S, Tafelmeier M, Messmann R, Provaznik Z, et al
Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease.
Eur J Heart Fail. 2020;22:2248-2257.
PubMed Abstract available

BHATT AS, Vaduganathan M
Discovery and care innovation amidst a pandemic.
Eur J Heart Fail. 2020;22:2202-2204.
PubMed

FARMAKIS D
Is cardio-oncology a rapidly growing field of precision medicine?
Eur J Heart Fail. 2020;22:2310-2313.
PubMed

KONSTAM MA
Ventricular remodelling: an equal-opportunity prognosticator.
Eur J Heart Fail. 2020;22:2269-2271.
PubMed

November 2020

PACKER M, Butler J, Filippatos G, Zannad F, et al
Design of a Prospective Patient-Level Pooled Analysis of Two Parallel Trials of Empagliflozin in Patients With Established Heart Failure.
Eur J Heart Fail. 2020 Nov 30. doi: 10.1002/ejhf.2065.
PubMed Abstract available

GREENBERG B, Janvanishstaporn S, Feng S
Reply to Letter: Worsening Renal Function After Diuresis Among Heart Failure Patients with Preserved Ejection Fraction --- A Dilemma to Heart Failure Management.
Eur J Heart Fail. 2020 Nov 29. doi: 10.1002/ejhf.2067.
PubMed

ANKER SD, Butler J, Filippatos G, Khan MS, et al
Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved Trial.
Eur J Heart Fail. 2020 Nov 29. doi: 10.1002/ejhf.2064.
PubMed Abstract available

BOORSMA EM, Beusekamp JC, Ter Maaten JM, Figarska SM, et al
Effects of Empagliflozin on Renal Sodium and Glucose Handling in Patients with Acute Heart Failure.
Eur J Heart Fail. 2020 Nov 29. doi: 10.1002/ejhf.2066.
PubMed Abstract available

ANKER MS, Sanz AP, Zamorano JL, Mehra MR, et al
Advanced cancer is also a heart failure syndrome - an hypothesis.
Eur J Heart Fail. 2020 Nov 28. doi: 10.1002/ejhf.2071.
PubMed Abstract available

MADELAIRE C, Kristensen SL
Patterns of unplanned readmissions after heart failure hospitalization: novel longitudinal perspectives from Australia and New Zealand.
Eur J Heart Fail. 2020 Nov 28. doi: 10.1002/ejhf.2068.
PubMed

D'AMARIO D, Borovac JA, Crea F
Coronary microvascular dysfunction in heart failure with preserved ejection fraction: not the end but the end of the beginning.
Eur J Heart Fail. 2020 Nov 28. doi: 10.1002/ejhf.2069.
PubMed

HALLIDAY BP, Owen R, Gregson J, Vassiliou V, et al
Myocardial remodelling after withdrawing therapy for heart failure in patients with recovered dilated cardiomyopathy - insights from TRED-HF.
Eur J Heart Fail. 2020 Nov 22. doi: 10.1002/ejhf.2063.
PubMed Abstract available

CANEPA M, Kapelios CJ, Lund LH
Acknowledging the complex puzzle that links heart failure hospitalizations and outcomes.
Eur J Heart Fail. 2020 Nov 22. doi: 10.1002/ejhf.2061.
PubMed

DONAL E, Galli E, Paven E, Sade LE, et al
Haemodynamic evaluation: a key tool for heart failure management.
Eur J Heart Fail. 2020 Nov 20. doi: 10.1002/ejhf.2055.
PubMed

BIEGUS J, Zymlinski R, Testani J, Marciniak D, et al
Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high risk acute heart failure patients.
Eur J Heart Fail. 2020 Nov 14. doi: 10.1002/ejhf.2053.
PubMed Abstract available

TOMASONI D, Inciardi RM, Lombardi CM, Tedino C, et al
Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study.
Eur J Heart Fail. 2020 Nov 12. doi: 10.1002/ejhf.2052.
PubMed Abstract available

VERNOOY K, Brunner-La Rocca HP
The importance of the electrocardiographic follow-up in heart failure.
Eur J Heart Fail. 2020 Nov 12. doi: 10.1002/ejhf.2054.
PubMed

DUSI V, Vitolo V, Frigerio L, Totaro R, et al
The First-in-Man Case of Non-invasive Proton Radiotherapy to Treat Refractory Ventricular Tachycardia in Advanced Heart Failure.
Eur J Heart Fail. 2020 Nov 12. doi: 10.1002/ejhf.2056.
PubMed

STARWALT JL, Ho AF, Wang H
Worsening Renal Function After Diuresis Among Heart Failure Patients with Preserved Ejection Fraction --- A Dilemma to Heart Failure Management.
Eur J Heart Fail. 2020 Nov 8. doi: 10.1002/ejhf.2050.
PubMed

KRESOJA KP, Rommel KP, Thiele H, Lurz P, et al
Response to the letter regarding the article: Transcatheter Tricuspid Valve Repair in the Setting of Heart Failure with Preserved or Reduced Left Ventricular Ejection Fraction.
Eur J Heart Fail. 2020 Nov 4. doi: 10.1002/ejhf.2048.
PubMed

KONIG S, Hohenstein S, Meier-Hellmann A, Kuhlen R, et al
In-hospital Care in Acute Heart Failure during the COVID-19 Pandemic: Insights from the German-wide Helios Hospital Network.
Eur J Heart Fail. 2020 Nov 2. doi: 10.1002/ejhf.2044.
PubMed Abstract available

FABRIS E, Sinagra G, Valgimigli M
Antithrombotic therapy in heart failure and sinus rhythm: the ongoing search for a better match of patients to therapy.
Eur J Heart Fail. 2020 Nov 1. doi: 10.1002/ejhf.2045.
PubMed

VOLTERRANI M, Perrone V, Sangiorgi D, Giacomini E, et al
Effects of hyperkalaemia and non-adherence to renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity-matched study.
Eur J Heart Fail. 2020;22:2049-2055.
PubMed Abstract available

Corrigendum to 'Departments involved during the first episode of acute heart failure and analysis of emergency department revisits and rehospitalisations: an outlook through the NOVICA cohort' [Eur J Heart Fail 2019;21:1231-1244].
Eur J Heart Fail. 2020;22:2172.
PubMed

JANKOWSKA EA, Tkaczyszyn M, Ponikowski P
Myocardial iron content in non-ischaemic cardiomyopathy: how much is known?
Eur J Heart Fail. 2020;22:2047-2048.
PubMed

RICHARDS AM
Beating the bushes for biomarkers.
Eur J Heart Fail. 2020;22:2075-2077.
PubMed

OKWUOSA TM, Keramida K, Filippatos G, Yancy CW, et al
Cancer therapy and the heart; the necessity to calibrate risk.
Eur J Heart Fail. 2020;22:1961-1965.
PubMed

SEFEROVIC PM, Polovina M
In search of a 'safety zone' for glycaemic control: association between glycosylated haemoglobin levels and outcomes in patients with type 2 diabetes and cardiovascular disease.
Eur J Heart Fail. 2020;22:2035-2037.
PubMed

KEHLER DS, Arora RC
Frailty and the failing heart do not travel alone.
Eur J Heart Fail. 2020;22:2120-2122.
PubMed

COWIE MR
DAPA-HF: does dapagliflozin provide 'bang for your buck' as a treatment for heart failure with reduced ejection fraction?
Eur J Heart Fail. 2020;22:2157-2159.
PubMed

October 2020

KOUDSTAAL S, Den Ruijter HM, Peters SAE
Sex Differences and Heart Failure - A Story of Two Tales.
Eur J Heart Fail. 2020 Oct 30. doi: 10.1002/ejhf.2041.
PubMed

WAGNER J, Ambrosy AP
Hospitalizations for Heart Failure and Mortality Risk During the Evolving Coronavirus Disease 2019 Pandemic - The Wave May Break but A Dangerous Undertow Persists.
Eur J Heart Fail. 2020 Oct 30. doi: 10.1002/ejhf.2043.
PubMed

AHMED F
Letter regarding the article Transcatheter Tricuspid Valve Repair in the Setting of Heart Failure with Preserved or Reduced Left Ventricular Ejection Fraction.
Eur J Heart Fail. 2020 Oct 30. doi: 10.1002/ejhf.2037.
PubMed

PELLICORI P, Platz E, Dauw J, Ter Maaten JM, et al
Ultrasound imaging of congestion in heart failure - Examinations beyond the heart.
Eur J Heart Fail. 2020 Oct 29. doi: 10.1002/ejhf.2032.
PubMed Abstract available

WHITELAW S, Sullivan K, Eliya Y, Alruwayeh M, et al
Trial characteristics associated with under-enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: A systematic review.
Eur J Heart Fail. 2020 Oct 29. doi: 10.1002/ejhf.2034.
PubMed Abstract available

KLOMPSTRA L, Kyriakou M, Lambrinou E, Piepoli MF, et al
Measuring physical activity with activity monitors in patients with heart failure. From literature to practice. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiol
Eur J Heart Fail. 2020 Oct 27. doi: 10.1002/ejhf.2035.
PubMed Abstract available

SIERPINSKI R, Josiak K, Suchocki T, Wojtas-Polc K, et al
High Soluble Transferrin Receptor in Patients With Heart Failure: a Measure of Iron Deficiency And a Strong Predictor of Mortality.
Eur J Heart Fail. 2020 Oct 27. doi: 10.1002/ejhf.2036.
PubMed Abstract available

BEKFANI T, Fudim M, Cleland JGF, Jorbenadze A, et al
A Current and Future Outlook on Upcoming Technologies in the Remote Monitoring of Patients with Heart Failure.
Eur J Heart Fail. 2020 Oct 27. doi: 10.1002/ejhf.2033.
PubMed Abstract available

CULIC V, Velat I
Spironolactone discontinuation in patients with heart failure: complex interactions with loop diuretics.
Eur J Heart Fail. 2020 Oct 23. doi: 10.1002/ejhf.2031.
PubMed

LABROSCIANO C, Horton D, Air T, Tavella R, et al
Frequency, Trends and Institutional Variation in 30-Day All-Cause Mortality and Unplanned Readmissions Following Hospitalisation for Heart Failure in Australia and New Zealand.
Eur J Heart Fail. 2020 Oct 23. doi: 10.1002/ejhf.2030.
PubMed Abstract available

DE BOER RA, Hulot JS, Gabriele Tocchetti C, Aboumsallem JP, et al
Common Mechanistic Pathways in Cancer and Heart Failure.
Eur J Heart Fail. 2020 Oct 22. doi: 10.1002/ejhf.2029.
PubMed Abstract available

SEFEROVIC PM, Fragasso G, Petrie M, Mullens W, et al
Heart Failure Association of the European Society of Cardiology Update on Sodium Glucose Co-transporter-2 Inhibitors in Heart Failure (an update on the Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. The position
Eur J Heart Fail. 2020 Oct 17. doi: 10.1002/ejhf.2026.
PubMed Abstract available

KOEHLER J, Stengel A, Hofmann T, Wegscheider K, et al
Telemonitoring in patients with chronic heart failure and moderate depressed symptoms - results of the Telemedical Interventional Monitoring in Heart Failure (TIM-HF) study.
Eur J Heart Fail. 2020 Oct 15. doi: 10.1002/ejhf.2025.
PubMed Abstract available

KASSNER A, Oezpeker C, Gummert J, Zittermann A, et al
Mechanical circulatory support does not reduce advanced myocardial fibrosis in patients with terminal heart failure.
Eur J Heart Fail. 2020 Oct 10. doi: 10.1002/ejhf.2021.
PubMed

SAED ALHAKAK A, Sengelov M, Jorgensen PG, Bruun NE, et al
Left Ventricular Systolic Ejection Time is an Independent Predictor of All-Cause Mortality in Heart Failure with Reduced Ejection Fraction.
Eur J Heart Fail. 2020 Oct 9. doi: 10.1002/ejhf.2022.
PubMed Abstract available

ABRAHAM WT, Psotka MA, Fiuzat M, Filippatos G, et al
Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel from the Heart Failure Collaboratory and Academic Research Consortium (HF-ARC).
Eur J Heart Fail. 2020 Oct 5. doi: 10.1002/ejhf.2018.
PubMed Abstract available

PUDIL R, Mueller C, Celutkiene J, Henriksen PA, et al
The role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and Cardio-Oncology Council of the European Society of Cardiology.
Eur J Heart Fail. 2020 Oct 2. doi: 10.1002/ejhf.2017.
PubMed Abstract available

COATS AJS
Pulmonary artery pressure monitoring, a reality for Europe?
Eur J Heart Fail. 2020;22:1905-1906.
PubMed

GUSTAFSSON F, Lund LH, Metra M
If it ain't broken, don't fix it (but if it is, make sure you know): aortic valve interventions during left ventricular assist device implantation.
Eur J Heart Fail. 2020;22:1888-1890.
PubMed

PARIKH PB, Tsigkas G, Kalogeropoulos AP
Transcatheter aortic valve replacement after heart failure hospitalization: too little, too late?
Eur J Heart Fail. 2020;22:1875-1877.
PubMed

ADAMO M, Metra M, Alfieri O
Percutaneous valve repair of functional mitral regurgitation: aiming at optimal and durable results.
Eur J Heart Fail. 2020;22:1849-1851.
PubMed

GRIFFIN JM, Maurer MS
Cardiac amyloidosis in severe aortic stenosis: we can find it but what should we do?
Eur J Heart Fail. 2020;22:1863-1865.
PubMed

SCHNEIDER M, Mascherbauer J
Improvement in nutritional status - a determinant of successful transcatheter tricuspid valve repair?
Eur J Heart Fail. 2020;22:1837-1839.
PubMed

September 2020

TEERLINK JR, Diaz R, Felker GM, McMurray JJV, et al
Omecamtiv Mecarbil in Chronic Heart Failure with Reduced Ejection Fraction, GALACTIC-HF: Baseline Characteristics and Comparison with Contemporary Clinical Trials.
Eur J Heart Fail. 2020 Sep 27. doi: 10.1002/ejhf.2015.
PubMed Abstract available

AHMAD A, Corban MT, Toya T, Verbrugge FH, et al
Coronary microvascular dysfunction is associated with exertional haemodynamic abnormalities in patients with heart failure with preserved ejection fraction.
Eur J Heart Fail. 2020 Sep 19. doi: 10.1002/ejhf.2010.
PubMed Abstract available

TOMASONI D, Adamo M, Metra M
September 2020 at a glance: focus on heart failure with preserved ejection fraction and medical therapy.
Eur J Heart Fail. 2020;22:1493-1494.
PubMed

KALOGEROPOULOS AP, Simitsis P, Skopicki HA
Secrets of spironolactone: continuing insights from TOPCAT Americas.
Eur J Heart Fail. 2020;22:1625-1627.
PubMed

RITCHIE R, Galougahi KK, Figtree GA
Targeting longevity genes in the battle against diabetic heart disease - is there a gene delivery fountain of youth?
Eur J Heart Fail. 2020;22:1582-1585.
PubMed

BISTOLA V, Polyzogopoulou E, Parissis J
A novel strategy for the management of lung congestion: targeting TRPV4 channel, the 'gate keeper' of pulmonary capillary permeability.
Eur J Heart Fail. 2020;22:1646-1648.
PubMed

ZIAEIAN B, Butler J, Fonarow GC
With great power comes great... reliability.
Eur J Heart Fail. 2020;22:1708-1710.
PubMed

August 2020

HOWLETT JG
The time has finally come to prioritize drug initiation before dose titration for patients with heart failure and reduced ejection fraction.
Eur J Heart Fail. 2020;22:1483-1485.
PubMed

MONTGOMERY RA, Tang WHW
A means to an end: the promise of tracking natriuresis with diuretic therapy.
Eur J Heart Fail. 2020;22:1448-1450.
PubMed

July 2020

VADUGANATHAN M, Pareek M, Kristensen AMD, Biering-Sorensen T, et al
Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy.
Eur J Heart Fail. 2020 Jul 21. doi: 10.1002/ejhf.1971.
PubMed Abstract available

EKSTROM K, Raisanen-Sokolowski A, Lehtonen J, Kupari M, et al
Long-term outcome and its predictors in giant cell myocarditis. Letter regarding the article 'Long-term outcome and its predictors in giant cell myocarditis'.
Eur J Heart Fail. 2020;22:1283-1284.
PubMed

SEFEROVIC PM, Asanin M, Polovina M
Practice makes perfect: improved long-term survival in non-ischaemic dilated cardiomyopathy with contemporary treatment.
Eur J Heart Fail. 2020;22:1122-1124.
PubMed

GORTER TM, van Veldhuisen DJ, Dickinson MG
Right-sided cardiac disease: no longer the 'dark side of the heart'.
Eur J Heart Fail. 2020;22:1226-1229.
PubMed

INCIARDI RM, Rossi A
Mitral regurgitation, edge-to-edge valve repair and the left atrium: one step beyond the left ventricle?
Eur J Heart Fail. 2020;22:1211-1213.
PubMed

SEFEROVIC PM, Polovina MM
A new perspective of an old tool: an everlasting benefit of the electrocardiogram in dilated cardiomyopathy.
Eur J Heart Fail. 2020;22:1108-1110.
PubMed

MICHEL L, Rassaf T, Totzeck M
Evaluating biomarkers as predictors of cancer therapy cardiotoxicity: all you need is a meta-analysis? Reply.
Eur J Heart Fail. 2020;22:1285-1286.
PubMed

AIMO A, Fabiani I, Emdin M
Evaluating biomarkers as predictors of cancer therapy cardiotoxicity: all you need is a meta-analysis?. Letter regarding the article 'Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis.'
Eur J Heart Fail. 2020;22:1284-1285.
PubMed

TER MAATEN JM, Said F, Maass AH
Factors predicting recovery of left ventricular dysfunction in non-ischaemic cardiomyopathy.
Eur J Heart Fail. 2020;22:1171-1173.
PubMed

ZWEERINK A, Allaart CP, Burri H
Shifting diastolic filling from right to left in non-obstructive hypertrophic cardiomyopathy: exploring new indications for biventricular pacing.
Eur J Heart Fail. 2020;22:1273-1275.
PubMed

June 2020

KLEIN P, Anker SD, Wechsler A, Kelle S, et al
Left ventricular volume reduction and reshape - 'Re-STICHING' the field. Reply.
Eur J Heart Fail. 2020;22:1053-1054.
PubMed

FERREIRA JP
Health-related quality of life scores: ending the minimum 5-point difference as the clinically meaningful threshold.
Eur J Heart Fail. 2020;22:1006-1008.
PubMed

BONIOS MJ, Kogerakis N, Adamopoulos SN
Left ventricular volume reduction and reshape - 'Re-STICHING' the field. Letter regarding the article 'Less invasive ventricular reconstruction for ischaemic heart failure'.
Eur J Heart Fail. 2020;22:1053.
PubMed

May 2020

HAWKINS NM, Osmanska J, Petrie MC
Implantable cardioverter-defibrillators and survival - the fine line between efficacy concerns and ageism.
Eur J Heart Fail. 2020;22:868-870.
PubMed

BOLLI R, Kahlon A
Time to end the war on cell therapy.
Eur J Heart Fail. 2020;22:893-897.
PubMed

FURTADO RHM, Bergmark B
Ejection fraction versus B-type natriuretic peptide for revascularization strategy in left main disease: two sides of the same coin or a wooden nickel?
Eur J Heart Fail. 2020;22:880-883.
PubMed

CHATTERJEE NA, Levy WC
Sudden cardiac death after myocardial infarction.
Eur J Heart Fail. 2020;22:856-858.
PubMed

April 2020

DE LUCA L, Savonitto S
Composite trends of cardiogenic shock complicating acute myocardial infarction.
Eur J Heart Fail. 2020;22:673-675.
PubMed

March 2020

STEWART COATS AJ
Validating the HFA-PEFF score - or how to define a disease?
Eur J Heart Fail. 2020;22:428-431.
PubMed

WESTIN O, Fosbol E, Gustafsson F
Refining the role of carpal tunnel syndrome in cardiac amyloidosis.
Eur J Heart Fail. 2020;22:516-518.
PubMed

SHEN L, Jhund P, McMurray J
Dyslipidaemia, a factor worthy of adjustment: reply.
Eur J Heart Fail. 2020;22:564-565.
PubMed

SKELIN M, Lucijanic M, Lucijanic J
Dyslipidaemia, a factor worthy of adjustment.
Eur J Heart Fail. 2020;22:564.
PubMed

February 2020

GRODIN JL, Rao A, Zaha VG
Myocardial dysfunction in breast cancer survivors: 'you can observe a lot by just watching'.
Eur J Heart Fail. 2020;22:347-349.
PubMed

MAGLIOCCA A, Omland T, Latini R
Dipeptidyl peptidase 3, a biomarker in cardiogenic shock and hopefully much more.
Eur J Heart Fail. 2020;22:300-302.
PubMed

RAJU B, McCullough PA
Circulating plasma dipeptidyl dipeptidase 3 and the prognosis of cardiogenic shock.
Eur J Heart Fail. 2020;22:287-289.
PubMed

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: